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A B S T R A C T
Background
Depression is an important consequence of stroke that influences recovery yet o(en is not detected, or is inadequately treated. This is an
update and expansion of a Cochrane Review first published in 2004 and previously updated in 2008.
Objectives
The primary objective is to test the hypothesis that pharmacological, psychological therapy, non-invasive brain stimulation, or
combinations of these interventions reduce the incidence of diagnosable depression a(er stroke. Secondary objectives are to test the
hypothesis that pharmacological, psychological therapy, non-invasive brain stimulation or combinations of these interventions reduce
levels of depressive symptoms and dependency, and improve physical functioning a(er stroke. We also aim to determine the safety of,
and adherence to, the interventions.
Search methods
We searched the Specialised Register of Cochrane Stroke and the Cochrane Depression Anxiety and Neurosis (last searched August 2018).
In addition, we searched the following databases; Cochrane Central Register of Controlled Trials, CENTRAL (the Cochrane Library, 2018,
Issue 8), MEDLINE (1966 to August 2018), Embase (1980 to August 2018), PsycINFO (1967 to August 2018), CINAHL (1982 to August 2018)
and three Web of Science indexes (2002 to August 2018). We also searched reference lists, clinical trial registers (World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP); to August 2018 and ClinicalTrials.gov; to August 2018), conference proceedings;
we also contacted study authors.
Selection criteria
Randomised controlled trials (RCTs) comparing: 1) pharmacological interventions with placebo; 2) one of various forms of psychological
therapy with usual care and/or attention control; 3) one of various forms of non-invasive brain stimulation with sham stimulation or usual
care; 4) a pharmacological intervention and one of various forms of psychological therapy with a pharmacological intervention and usual
care and/or attention control; 5) non-invasive brain stimulation and pharmacological intervention with a pharmacological intervention
and sham stimulation or usual care; 6) pharmacological intervention and one of various forms of psychological therapy with placebo
and psychological therapy; 7) pharmacological intervention and non-invasive brain stimulation with placebo plus non-invasive brain
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stimulation; 8) non-invasive brain stimulation and one of various forms of psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control; and 9) non-invasive brain stimulation and one of various forms of psychological therapy versus
sham brain stimulation or usual care plus psychological therapy, with the intention of preventing depression a(er stroke.
Data collection and analysis
Review authors independently selected studies, assessed risk of bias, and extracted data from all included studies. We calculated mean
diEerence (MD) or standardised mean diEerence (SMD) for continuous data and risk ratio (RR) for dichotomous data with 95% confidence
intervals (CIs). We assessed heterogeneity using the I2 statistic and assessed the certainty of evidence using GRADE.
Main results
We included 19 RCTs (21 interventions), with 1771 participants in the review. Data were available for 12 pharmacological trials (14
interventions) and seven psychological trials. There were no trials of non-invasive brain stimulation compared with sham stimulation
or usual care, a combination of pharmacological intervention and one of various forms of psychological therapy with placebo and
psychological therapy, or a combination of non-invasive brain stimulation and a pharmacological intervention with a pharmacological
intervention and sham stimulation or usual care to prevent depression a(er stroke. Treatment eEects were observed on the primary
outcome of meeting the study criteria for depression at the end of treatment: there is very low-certainty evidence from eight trials (nine
interventions) that pharmacological interventions decrease the number of people meeting the study criteria for depression (RR 0.50, 95%
CI 0.37 to 0.68; 734 participants) compared to placebo. There is very low-certainty evidence from two trials that psychological interventions
reduce the proportion of people meeting the study criteria for depression (RR 0.68, 95% CI 0.49 to 0.94, 607 participants) compared to
usual care and/or attention control.
Eight trials (nine interventions) found no diEerence in death and other adverse events between pharmacological intervention and placebo
groups (RR 1.25, 95% CI 0.32 to 4.91; 496 participants) based on very low-certainty evidence. Five trials found no diEerence in psychological
intervention and usual care and/or attention control groups for death and other adverse events (RR 1.18, 95% CI 0.73 to 1.91; 975
participants) based on very low-certainty evidence.
Authors' conclusions
The available evidence suggests that pharmacological interventions and psychological therapy may prevent depression and improve
mood a(er stroke. However, there is very low certainty in these conclusions because of the very low-certainty evidence. More trials are
required before reliable recommendations can be made about the routine use of such treatments a(er stroke.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for preventing depression aer stroke
Review question
Do pharmacological, psychological, non-invasive brain stimulation or a combination of these interventions prevent depression and
improve outcomes a(er stroke?
Background
The role of interventions for preventing depression a(er stroke is unclear. Depression is a common and important complication of stroke
that is o(en missed or poorly managed. Little is known about whether prevention strategies started early a(er stroke will reduce the risk
of depression and improve recovery for those not depressed at assessment.
Search date
We identified trials using searches conducted on 13 August 2018.
Study characteristics
We included trials which reported on the use of pharmacological and psychological interventions to prevent depression a(er stroke.
Average age of participants ranged from 55 to 73 years. Trials were from Asia (3), Europe (8), North America (5), and Australia (3).
Key results
We included 19 trials (12 pharmacological and seven psychological) involving 1771 participants. Outcome information was available for
nine pharmacological and two psychological trials, which suggested that these treatments might reduce the risk of developing depression.
A smaller number of studies (eight pharmacological and five psychological studies) found no increase in death or adverse events.
Certainty of evidence
We rated the certainty of evidence as very low due to limitations in study design.
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Conclusion
Our ability to generalise these findings to all stroke survivors is limited due to the small proportion of survivors who were eligible to
participate in these clinical trials. More well-designed clinical trials are needed that test practical interventions for preventing depression
across all stroke survivors.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Pharmacological interventions (antidepressants) compared to placebo for preventing depression aer stroke
Pharmacological interventions (antidepressants) compared to placebo for preventing depression after stroke
Patient or population: people with stroke
Setting: hospital and community
Intervention: pharmacological interventions (antidepressants)
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes














study criteria for depres-
sion at end treatment
(Analysis 1.1)










points for a depressive
disorder at end of treat-
ment (Analysis 1.2)
- - (0 RCTs) - No data available.
Depression: mean scores at end of treatment
(Analysis 1.4)
MD 0.59 higher





HDRS (high score = more de-
pressed)
Cognition: mean scores at end of treatment
(Analysis 1.6)
MD 0.42 lower





MMSE (low score = cognitive im-
pairment)
Activities of daily living: mean scores at end of
treatment (Analysis 1.8)
MD 3.86 lower





Barthel Index (high score = more
dependent)
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Johns Hopkins Functioning In-
ventory (high score = less func-
tion)
Study populationAdverse events: death
- at end of treatment









*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; HDRS: Hamilton Depression Rating Scale; MMSE: Mini Mental State Examination; MD: mean difference; RCT: randomised controlled trial; RR: risk
ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the certainty of evidence as the studies were rated as unclear or high risk in multiple risk of bias domains.
bWe downgraded the certainty of evidence because the confidence intervals were wide.
cWe downgraded the certainty of evidence because the confidence intervals were very wide.
 
 
Summary of findings 2.   Psychological therapy compared to usual care and/or attention control for preventing depression aer stroke
Psychological therapy compared to usual care and/or attention control for preventing depression after stroke
Patient or population: people with stroke
Setting: hospital and community
Intervention psychological therapy
Comparison: usual care and/or attention control
Anticipated absolute effects* (95% CI)Outcomes














Study populationDepression: meeting study criteria for de-
pression at end of treatment (Analysis 2.1)















































































































































































Scoring above cut-oE points for a depres-
sive disorder at end of treatment (Analysis
2.2)
- - - (0 RCTs) - No data available
Depression: mean scores at end of treatment (Analysis 2.3) - - 132
(2 studies)
- No totals
HDRS (high score =
more depressed)
MADRS (high score =
more depressed)













Profile (high score =
better health)
Social activities: mean scores at end of treatment (Analysis 2.10) MD 0.39 lower







Index (high score =
better level of activi-
ty)




score = more depen-
dent)
Nottingham Extend-
ed Activities of dai-
ly living (high score =
more independent)
Study populationAdverse events: death - at end of treat-
ment (Analysis 2.16)















































































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; GHQ-28: 28-item General Health Questionnaire; HDRS: Hamilton Depression Rating Scale; MADRS: Montgomery Aserg Depression Rating Scale; MD:
mean difference; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aWe downgraded the certainty of evidence as the studies were rated high risk in multiple risk of bias domains.
bWe downgraded the certainty of evidence because the confidence intervals were wide.
cWe downgraded the certainty of evidence because the confidence intervals were very wide.
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B A C K G R O U N D
Description of the condition
Depressive and anxiety disorders are important sequelae of
stroke, occurring in up to half of people in the first year a(er
onset, although estimates diEer between studies due to varying
definitions, populations, exclusion criteria, and the timing of
assessments (Ayerbe 2013; Hackett 2014). Although there is
much controversy surrounding stroke-associated depression as a
specific type of depressive syndrome, the condition may impede
rehabilitation (Parikh 1990; Sinyor 1986), by impairing physical and
cognitive function (Robinson 1986), and contributing to stress on
carers (Anderson 1995). Furthermore, depression following stroke
may also be associated with an increased risk of death (House
2001; Morris 1993), including death by suicide (Stenager 1998).
Depressive illness among older people, in general, is associated
with greater morbidity and dependency, higher use of drugs
and alcohol, increased use of healthcare resources, and poor
compliance with treatment of co-morbid conditions (Katona 1995).
Description of the intervention
We considered three broad interventions in this review.
• Pharmacological interventions designed to prevent depression:
there are several classes of relevant pharmacological agents
including selective serotonin reuptake inhibitors (SSRIs) (e.g. le
fluvoxamine, fluoxetine, sertraline, citalopram, and paroxetine),
serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g.
venlafaxine, milnacipran, sibutramine), monoamine oxidase
inhibitors (MAOIs) (e.g. moclobemide), tricyclic antidepressants
(TCAs) (e.g. nortriptyline, imipramine, and clomipramine), and
other antidepressant medications including psychostimulants
(e.g. methylphenidate), mood stabilisers (e.g. lithium), or
benzodiazepines.
• One of various forms of psychological intervention (talking
therapy) designed to prevent depression: as there are many
potential therapies we included any psychological intervention
that involved direct person-professional interaction. The
content of the interaction could vary from counselling to specific
psychotherapy provided it was directed at helping people
develop their social problem-solving skills and adjustment to
the emotional impact of stroke. All interventions had to have
a psychological component - talking, listening, support, advice;
be based on a theory of talking therapy; be structured and
time-tabled as a talking therapy; and be delivered by somebody
with some explicitly stated training and supervision in therapies.
The person-professional interaction could take place in person,
via telephone or other media. We did not include web-based
interventions even if mediated by a health professional. We
did not include interventions based upon self-management or
supported self-management.
• Non-invasive brain stimulation designed to prevent depression:
electroconvulsive therapy (ECT) involves the brief passage of an
electrical current through the brain via electrodes applied to the
scalp to induce a generalised seizure (i.e. a fit or convulsion).
The seizure comprises two components: a central element, the
ictus involving depolarisation (i.e. discharge of neurotransmitter
chemicals) of brain cells, and a peripheral element of convulsive,
jerking movements of the body, although this is now modified
due to use of a short-acting anaesthetic and muscle relaxant,
as part of what is called modified ECT. Modified ECT replaced
the initial crude equipment and techniques of unmodified ECT
from the mid-1950s. The seizure is detected by electrodes
placed on the scalp to monitor brain electrical activity (i.e.
EEG). The ECT electrodes can be placed on both sides of the
head (bilateral placement), or on one side, usually the right
side of the head (unilateral placement). The passage of an
electrical current through the skull to the brain is necessary
to trigger a seizure. In this update, we expanded the review to
include other non-invasive brain stimulation techniques such as
1) transcranial magnetic stimulation or repetitive transcranial
magnetic stimulation (TMS or rTMS, where a magnetic 'coil'
is placed near the head of the person receiving the treatment
without making physical contact); 2) transcranial direct current
stimulation (tDCS, where a constant, low current is delivered
directly to the brain area of interest via small electrodes); 3)
cranial electrotherapy stimulation (CES, where a small, pulsed
electric current is applied across a person's head), and 4)
magnetic seizure therapy (MST), a type of convulsive therapy
that involves replacing the electrical stimulation used in ECT
with a rapidly alternating strong magnetic stimulation.
We further considered these combinations of the three broad
interventions.
• Pharmacological intervention and one of various forms of
psychological therapy with a pharmacological intervention and
usual care and/or attention control.
• Pharmacological intervention and one of various forms of
psychological therapy with placebo and psychological therapy.
• Pharmacological intervention and non-invasive brain
stimulation with a pharmacological intervention and sham
stimulation or usual care.
• Pharmacological intervention and non-invasive brain
stimulation with placebo plus non-invasive brain stimulation.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual
care plus psychological therapy.
How the intervention might work
Pharmacological interventions are thought to alter the synaptic
transmission process in the brain to increase neurotransmission,
for example serotonin reuptake SSRIs are intended to block the
transport of serotonin, SNRIs are designed to increase the levels of
serotonin and norepinephrine, and TCAs are designed to block the
reuptake of norepinephrine.
Psychological interventions focus on changing thought, emotional,
behavioural, and relationship patterns. During psychological
interventions, trained therapists work with individuals to help
them see patterns in their thoughts, emotions, behaviours, or
relationships that may be problematic. The therapist's role is
to help a person understand the patterns and assist them in
developing ways to overcome them.
During modified ECT a small amount of electric current is passed
briefly across the brain to cause an artificial epileptic fit that
aEects the entire brain. Repeated ECT is believed to alter chemical
pathways in the brain that are responsible for depression. The
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression a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exact mechanism of action of TMS, rTMS, tDCS, and CES remains
unclear. They are thought to induce intracerebral current flow,
increase or decrease neuronal excitability and/or activate nerve
cells in the specific area being stimulated. MST involves replacing
the electrical stimulation used in ECT with a magnetic stimulus,
which is purported to produce similar clinical eEects but without
the cognitive side eEects.
Why it is important to do this review
Although depression may influence recovery and outcome
following stroke, many, perhaps most, people do not receive
eEective treatment because their mood disorder is undiagnosed or
inadequately treated (Ebrahim 1987; Hackett 2005a; House 1989).
This is due in part to the problems with the diagnosis of a significant
mood state among older people with disability. Even in otherwise
healthy individuals, the assessment of abnormal mood is fraught
with diEiculty. Information from the general population suggests
that, despite the severity and possible complications, only half
of those with depression will seek professional help (WHO 2000).
This may be due to the stigma associated with a diagnosis, people
not realising they are unwell, or feeling their condition is beyond
help, a natural part of ageing or a consequence of stroke. Given
the problems inherent with diagnosis, that people are at high
risk of developing depression a(er stroke, and the uncertainty
about the balance of benefit and risks of treatment, there is
interest in therapies commenced early a(er the onset of stroke
that prevent abnormal mood and improve outcome. We undertook
a systematic review of all randomised controlled trials (RCTs),
both published and unpublished, of pharmacological agents,
psychological interventions, non-invasive brain stimulation, or
their combination for the prevention of depression associated with
stroke. This is an update of a Cochrane Review first published in
2004 (Anderson 2004), and last updated in 2008 (Hackett 2008).
O B J E C T I V E S
Primary objective
• To determine whether pharmacological therapy, psychological
therapy, non-invasive brain stimulation or combinations of
these interventions prevent the incidence of diagnosable
depression a(er stroke.
Secondary objectives
• To determine whether pharmacological therapy, psychological
therapy, non-invasive brain stimulation or combinations of
these interventions reduce levels of depressive symptoms,
improve physical and neurological function and health-related
quality of life, and reduce dependency a(er stroke.
• To assess the safety of, and adherence to such treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We restricted the review to all relevant randomised controlled trials
(RCTs). There was no restriction on eligibility of RCTs on the basis
of language, sample size, duration of follow-up, or publication
status. Trials that met all the inclusion criteria, but in which no
outcome data were available (either from the report of the trial or
from the authors), could not contribute meaningfully to a pooled
estimate of eEect. These trials were regarded as 'dropouts' rather
than ineligible and we have listed them in an additional table to
indicate that they have not been overlooked (Table 1).
Types of participants
We included all participants with a confirmed history of stroke
where there was an explicit intention to provide an intervention
to prevent depression associated with stroke. Stroke was defined
according to clinical criteria. The criteria included cerebral
infarction, intracerebral haemorrhage, and uncertain pathological
subtypes, but excluded studies of subarachnoid haemorrhage
(SAH) only, which has a diEerent natural history and management
strategy to other stroke subtypes. We included studies with small
numbers of participants with SAH. We excluded trials that included
mixed populations (such as stroke and head injury or other central
nervous system disorders) unless separate results for participants
with stroke were identified. We excluded participants with a
diagnosed depressive disorder or a mood score above the standard
cut-oE score for depressive disorder at baseline, but included
them in a review of pharmacological, psychological and non-
invasive brain stimulation interventions for treating depression
a(er stroke (Allida 2020). We excluded participants if they were
treated primarily for a stroke-associated pain syndrome or other
physical disorder, even if depression was measured as a secondary
outcome.
Types of interventions
We included the following interventions.
• Comparison between a pharmacological intervention and
placebo for the prevention of depression a(er stroke. Specific
pharmacological agents included tricyclic antidepressants
(e.g. nortriptyline, imipramine, and clomipramine), selective
serotonin reuptake inhibitors (SSRIs) (e.g. fluvoxamine,
fluoxetine, sertraline, and paroxetine), monoamine oxidase
inhibitors (MAOIs) (e.g. moclobemide), and other
antidepressant medications. We included psychostimulants
(e.g. methylphenidate), mood stabilisers (e.g. lithium),
benzodiazepines, and combined preparations, but analysed
these separately.
• Comparison between psychological therapy and usual care (or
attention control) for the prevention of depression a(er stroke.
We included any psychological therapy that involved direct
person-professional interaction. The content of the interaction
could vary from counselling to specific psychological therapy,
provided it was directed at helping people develop their
social problem-solving skills and adjustment to the emotional
impact of stroke. All interventions had to have a psychological
component, such as talking, listening, support, advice; be based
on a theory of talking therapy; be structured and time-tabled
as a talking therapy; and be delivered by somebody with some
explicitly stated training and supervision in therapies.
• Comparison between non-invasive brain stimulation and sham
stimulation or usual care for the prevention of depression
associated with stroke. We found no trials of non-invasive brain
stimulation interventions. Any future trials will be included but
analysed separately.
Alternatively, we included their combinations.
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• Pharmacological intervention and one of various forms of
psychological therapy versus pharmacological intervention plus
usual care and/or attention control.
• Pharmacological intervention and one of various forms of
psychological therapy versus placebo plus psychological
therapy.
• Pharmacological intervention and non-invasive brain
stimulation versus pharmacological intervention plus sham
stimulation or usual care.
• Pharmacological intervention and non-invasive brain
stimulation versus placebo plus non-invasive brain stimulation.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus non-invasive brain stimulation
plus usual care and/or attention control.
• Non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual
care plus psychological therapy.
Exclusions included the following.
• Interventions with an agent or therapy that was being primarily
evaluated for other reasons (for example, to improve physical
function, provide neuroprotection, or to facilitate neuro-
regeneration) with a mood endpoint.
• Interventions with the sole purpose of educating or providing
information.
• Occupational therapy (including leisure therapy and other
rehabilitation services).
• Acupuncture or electro-acupuncture.
• Herbal medicines.
• Interventions which involved visits from stroke support workers,
unless there was a clearly defined psychological component.
Attention control in psychological therapy trials can include non-
specific interventions such as relaxation classes, or follow-up with
a clinician who has no psychological training.
Types of outcome measures
Primary outcomes
The primary analyses focus on the proportion of people who met
the diagnostic categories of depression that were applied by the
authors of the trial, at the end of the treatment period. These
included:
• meeting the criteria for depression, dysthymia or minor
depression as defined by the American Psychiatric Association
Diagnostic and Statistical Manual of Mental Disorders (DSM-IIIR,
DSM-IV, DSM V; APA 1987; APA 1994; APA 2013) or similar standard
diagnostic criteria;
• scoring above cut-oE points for a depressive disorder, as defined
by symptom scores on standard mood rating scales.
Secondary outcomes
The secondary outcomes were:
• depression score, as measured on scales such as the Hamilton
Depression Rating Scale (HDRS, Hamilton 1960), Montgomery
Åsberg Depression Rating Scale (MADRS, Montgomery 1979),
Geriatric Depression Scale (GDS, Gompertz 1993), Beck
Depression Inventory (BDI, Beck 1961), and Hospital Anxiety and
Depression Scale (HADS Depression sub-scale, Zigmond 1983) at
the end of treatment/follow-up;
• psychological distress, as measured on composite scales such as
the General Health Questionnaire (GHQ, Goldberg 1972);
• general health, as measured on composite scales such as the
Nottingham Health Profile (NHP, Hunt 1986);
• cognition, as measured on scales such as the Mini-Mental State
Examination (MMSE, Folstein 1975);
• social activities, as measured on scales such as the Frenchay
Activities Index (FAI, Wade 1985);
• activities of daily living, as measured on scales such as the
Barthel Index (BI, Mahoney 1965);
• disability, as measured on scales such as the Hemispheric Stroke
Scale (HSS, Adams 1990);
• disadvantages of treatment, recorded as adverse events;
grouped by death, all, and leaving the study early (including
death).
We examined the reason for participants withdrawing from the
studies as a marker of acceptance.
We have identified additional outcomes, where measured, for use
in further reviews.
• Anxiety, as measured on scales such as the Hamilton Anxiety
Scale, Beck Anxiety Inventory, and the Hospital Anxiety and
Depression Scale (HADS Anxiety sub-scale, Zigmond 1983).
Search methods for identification of studies
This review is an update of a previously published Cochrane Review
updated in 2008 (Hackett 2008; Appendix 1). The first published
review was in 2004 (Anderson 2004). For this update, we searched
all databases from inception until August 2018. We searched for
relevant trials in all languages and arranged for translation of trial
reports when necessary.
Specialised Register of Cochrane Stroke
See the methods for the Cochrane Stroke Group Specialised
register. The Cochrane Stroke Group Information Specialist
searched the Specialised Register of Cochrane Stroke on 13 August
2018.
Electronic searches
We searched the following bibliographic databases.
• Cochrane Depression Anxiety and Neurosis Trials Register (last
searched August 2018)
• Cochrane Central Register of Controlled Trials (CENTRAL; 2018,
Issue 8), in the Cochrane Library (Appendix 2)
• MEDLINE (OVID):1966 to August 2018 (Appendix 3)
• Embase (OVID): 1980 to August 2018 (Appendix 4)
• PsycINFO (OVID): 1967 to August 2018 (Appendix 5)
• Cumulative Index to Nursing and Allied Health Literature,
CINAHL (EBSCO): 1982 to August 2018 (Appendix 6)
• Science Citation Index - Expanded (SCI-EXPANDED), Social
Sciences Citation Index (SSCI), and Arts & Humanities Citation
Index (A&HCI) in Web of Science (ISI): 2002 to August 2018
(Appendix 7)
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Biological Abstracts has now been superseded by ISI Web of
Science, which includes the Arts and Humanities Index. Several
databases/citation indexes (Applied Science and Technology Plus;
Biological Abstracts; BIOSIS Previews; General Science Plus;
Dissertations and Theses) listed in Appendix 1 were not used for this
update.
We also searched the following ongoing trials registers and
registries using 'stroke' or 'brain infarction' or 'depression' or 'low
mood' from inception to August 2018.
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov)
• World Health Organization International Clinical Trials Registry
Platform ( WHO ICTRP) (www.who.int/ictrp/en/)
Searching other resources
In addition, we also searched abstracts and conference proceedings
from the following international conferences for relevant studies.
• European Stroke Organisation Conference (2015 to 2018)
• Stroke Society of Australasia Annual Scientific Meetings (2008 to
2018)
• World Stroke Congress (2000 to 2016)
• Asia Pacific Stroke Conference (2011 to 2017)
The full search strategies for other resources are presented in
Appendix 8.
Personal communication
We contacted the study authors for information on ongoing and
'dropout' trials or to request additional study data and in some
instances, additional analyses.
Reference lists
We searched the reference lists of relevant trials, systematic reviews
and reviewed chapters in books on the prevention and treatment of
depression and management of stroke, including but not limited to,
reviews of the management of stroke, books specifically directed at
the treatment or prevention of depression, and those on stroke and
old age.
Data collection and analysis
Selection of studies
Two review authors (SA, KC) reviewed all citations for this update
and discarded those that were irrelevant, based on the title of the
publication and its abstract. In the presence of any suggestion that
an article was possibly relevant, we retrieved the full-length article
for further assessment. Two review authors (SA, KC) independently
selected the trials for inclusion in the review from the culled citation
list. Potentially relevant Chinese language articles were translated
by another study author (C-FH). We resolved disagreements by
discussion, and MH and AH confirmed the final list and adjudicated
any persisting diEerences of opinion. The selection process is
presented in a PRISMA flow diagram (Figure 1). We listed the
included studies under Characteristics of included studies, and
studies that we ultimately excluded under Characteristics of
excluded studies and provided the primary reasons for exclusion.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Data extraction and management
Four review authors (SA, KC, C-FH, MH) independently extracted
the study characteristics and outcome data from studies included
in this update, on specially designed forms. We cross-checked and
entered the data into Review Manager 5 (Review Manager 2014).We
resolved disagreements by discussion or through consultation
with two other review authors (AH or MH). We obtained missing
information from the study authors when possible. Information
on funding sources are mentioned in the notes section of the
Characteristics of included studies table.
We collected data on:
• the report: author, year, and source of publication;
• the study: sample characteristics, social demography, definition
and criteria used for depression;
• the participants: stroke sequence (first ever versus recurrent),
social situation, time elapsed since stroke onset, history
of psychiatric illness, current neurological status, current
treatment for depression, and a history of coronary artery
disease;
• the research design and features: sampling mechanism,
treatment assignment mechanism, adherence, non-response,
and length of follow-up;
• the intervention: type, duration, dose, timing, and mode of
delivery;
• the eEect size: sample size, nature of outcome, estimate and
standard error on x dy = SD.
To allow for intention-to-treat (ITT) analysis, we sought the
data irrespective of adherence, fidelity of the intervention to
the protocol, and regardless of whether the participants were
subsequently deemed ineligible or otherwise excluded from
treatment or follow-up. Where study authors used multiple
measures to assess depression, we extracted data from the
measure the study authors stated was used to assess the
primary outcome. For measures assessing secondary outcomes,
we extracted data from the most commonly used measure.
Where data for the same trial endpoint were conflicting across
multiple publications, we extracted data from the first publication
reporting data for that outcome. We checked all the extracted
data for agreement between review authors. We obtained missing
information from the primary investigators whenever possible. To
avoid introducing bias, we obtained this unpublished information
in writing, on forms designed for the purpose, and entered it into
RevMan.
Assessment of risk of bias in included studies
Three review authors (SA, KC, C-FH) independently assessed risk of
bias for each new study using the criteria outlined in Section 8.1
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2019). We resolved any disagreements by discussion or by
involving another review author (MH). Although there are a number
of scales devised for assessing the quality of RCTs, there is no
convincing evidence that complex and time-consuming scales are
more eEective than simple scales (Verhagen 2001). We assessed the
risk of bias according to the following domains.
• Random sequence generation.
• Allocation concealment: If allocation was performed using
opaque envelopes we also categorised this as ’high risk’ as it is
not tamper-proof.
• Blinding of participants and personnel: For psychological
interventions, we recognise that participants are unlikely to
remain blinded however, we also categorised this as ’high risk’.
• Blinding of outcome assessment.
• Incomplete outcome data
• Selective outcome reporting: when a published trial protocol
was not available we categorised this as unclear risk.
• Other bias.
We also provided a quote from the study to justify our judgment
in the 'Risk of bias in included studies' table. When considering
treatment eEects, we have taken into account the risk of bias for the
studies that contributed to that outcome.
Measures of treatment e;ect
Dichotomous data
For all dichotomous outcomes, we calculated risk ratios (RRs) with
95% confidence intervals (CIs) where appropriate, using random-
eEects analyses.
Continuous data
For continuous data, if ordinal scale data appeared to be normally
distributed, or if the analysis suggested parametric tests were
appropriate, we treated the outcome measures as continuous. If
there were at least two trials that reported the same outcomes,
then we calculated a mean diEerence (MD) with 95% CIs across the
trials. Where diEerent outcome measures were used, we calculated
a standardised mean diEerence (SMD) with 95% CIs.
Unit of analysis issues
We predicted that randomisation would occur at the level of
the individual participant in most, if not all, trials. Outcomes
are reported at the end of treatment, and the end of follow-up,
where data are available. Where trials included two or more active
intervention arms and only one control arm (placebo, attention
control, or usual care), we compared data from each treatment
arm with data from the total number of participants in the control
group, divided by the number of active intervention groups. The
comparisons are presented as separate trials.
Dealing with missing data
We wrote to the authors of all included, ongoing, and dropout
trials requesting data that were unavailable or ambiguous in the
published articles. We received responses with additional data
from the study authors of four new trials (HoEman 2015; Kerr 2018;
Robinson 2008; Wichowicz 2017). In 2008, we received responses
with additional data from authors of two trials (Almeida 2006;
Watkins 2007). In 2004 we received responses about six trials
(Downes 1995; Forster 1996; Friedland 1992; House 2000; Reding
1986; Robinson 2000a; Sitzer 2002). We received a response from
one further author, but no additional data had been provided by the
time of publication (Rasmussen 2003). We received no responses
from the remaining authors. We also wrote to all pharmaceutical
companies known to produce, or have a licence to produce,
pharmacological interventions in 2004. We received nine replies
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identifying no new trials, so we did not repeat this in the 2008 or
current update.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by
examining the study characteristics. We used the I2 statistic to
measure heterogeneity among the trials in each analysis (Deeks
2011). If there were at least two trials that reported the same
outcomes, we reviewed the data for appropriateness of pooling.
We interpreted the amount of heterogeneity as low (0% to
29%), moderate (30% to 49%), substantial (50% to 89%), and
considerable (90% to 100%) I2 values. We reported similarities
between interventions, participants, design, and outcomes in the
included trials subsection.
Assessment of reporting biases
We assessed publication bias by a funnel plot only if there were
10 or more included trials (Higgins 2019), using depression as
the outcome of interest. We attempted to avoid language bias
by including trials irrespective of language of publication, and
translation was performed where needed by native speakers of that
language. Review author (C-FH) translated and extracted data for
the Chinese language papers. In some cases, similarities between
trial reports indicated the possibility of multiple publications from
the same trial. We contacted the authors to check whether the
publications were duplicates. In the absence of a response and
explicit cross-referencing, we judged articles to be from the same
trial if they met the following criteria: 1) there was evidence
of overlapping recruitment sites, study dates, and grant funding
numbers, and 2) there were similar or identical reported participant
characteristics in the trials.
Data synthesis
We analysed data using Review Manager so(ware and pooled
data for meta-analysis when trials assessed similar treatments and
had similar outcomes (Review Manager 2014). We conducted a
meta-analysis using available calculated mean diEerence (MD) or
standardised mean diEerences (SMD) for continuous outcomes,
and risk ratios (RRs) for dichotomous outcomes using a random-
eEects analyses. In the results we included measures of uncertainty,
such as 95% confidence intervals (CIs) and estimates of I2. For all
summary statistics in this review, please refer to the eEects at the
end of intervention, or at the end of follow-up.
Summary of findings and certainty of the evidence
We also assessed the certainty of evidence according to GRADE
(Atkins 2004), by constructing a 'Summary of findings' table for
the main outcomes per comparison using the GRADEPro tool
(GRADEproGDT 2015; Schünemann 2019). We reported the relevant
outcomes in the 'Summary of findings' table for each comparison.
These data were available for comparison: (1) pharmacological
interventions versus placebo; and (2) one of various forms of
psychological therapy versus usual care and/or attention control.
For the comparison 'Pharmacological intervention versus placebo',
we reported the certainty of evidence for the following outcomes:
meeting the study criteria for depression, scoring above cut-oE
points for a depressive disorder, mean depression scores, mean
cognition scores, mean activities of daily living scores, and death at
the end of treatment.
For the comparison 'Psychological interventions versus usual care
and/or attention control', we reported the certainty of evidence for
the following outcomes: meeting the study criteria for depression,
scoring above cut-oE points for a depressive disorder, mean
depression scores, mean psychological distress scores, mean
general health scores, mean social activities score, and death at the
end of treatment.
We had no data for the remaining comparisons: (3) non-
invasive brain stimulation and sham stimulation or usual care;
(4) pharmacological intervention and one of various forms
of psychological therapy versus pharmacological intervention
plus usual care and/or attention control; (5) pharmacological
intervention and one of various forms of psychological
therapy versus placebo plus psychological therapy; (6)
pharmacological intervention and non-invasive brain stimulation
versus pharmacological intervention plus sham stimulation
or usual care; (7) pharmacological intervention and non-
invasive brain stimulation versus placebo plus non-invasive
brain stimulation; (8) non-invasive brain stimulation and one
of various forms of psychological therapy versus non-invasive
brain stimulation plus usual care and/or attention control; and
(9) non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual care
plus psychological therapy. See Types of interventions.
Subgroup analysis and investigation of heterogeneity
We planned to undertake subgroup analyses to explore the
influence of date of publication, sample size, duration of follow-up,
treatment type, high (over 20%) number of dropouts, and blinded
versus unblinded outcome assessors. We performed subgroup
analyses by method of assessment and outcome measures
used to assess depression, psychological distress, general health,
cognition, social activities, activities of daily living (ADL), disability,
and anxiety for all comparisons.
If there were at least two trials that reported the same outcomes,
we reviewed the data for appropriateness of pooling. If there
was definite evidence of heterogeneity (I2 > 50%), we explored
the potential reasons for the diEerences by performing subgroup
analyses and meta-regression (Normand 1999). If the heterogeneity
could not be explained, we combined the trials using random-
eEects analyses with cautious interpretation, or did not combine
them at all. Where possible, we performed subgroup analyses to
examine the impact of treatment type and duration, and of stroke
severity.
Sensitivity analysis
We planned to explore the sensitivity of the combined estimate
of individual trials by leaving out one study if there was high risk
of bias and methodological diEerences. We then calculated the
combined eEect of the remaining trials, and compared the results
with the combined eEect based on all the trials.
R E S U L T S
Description of studies
Results of the search
In total, we identified 23,228 records, of these we retrieved 22,297
through database searching. We found 931 additional references
by searching other resources. A(er duplicates were removed, we
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screened 9100 titles and abstracts and excluded 9069 irrelevant
records. We retrieved full-text reports for the remaining 31 studies.
A(er reading the full-texts, we excluded 17 studies as they did not
meet the review eligibility criteria. We have provided the primary
reasons for exclusions in the Characteristics of excluded studies
table and Figure 1. We identified two trials that met the inclusion
criteria (Hadidi 2014; Kim 2017). However, data were not available
for non-depressed participants only. These trials are considered
'dropouts' (Table 1).
In the previous published version of this review (Hackett 2008),
eight trials (Bramanti 1989; Downes 1995; Friedland 1992; GraEingo
2003; Leathley 2003; McCaEerty 2000; Ohtomo 1985; RaEaele 1996)
met the inclusion criteria but were considered ’dropouts’ as data
were not available for non-depressed participants only (Downes
1995; RaEaele 1996), and were either not available or not in a
suitable format for meta-analysis (Bramanti 1989; Friedland 1992;
GraEingo 2003; Leathley 2003; McCaEerty 2000; Ohtomo 1985). See
Table 1 for a more detailed information on these trials.
We received responses with additional data from authors of three
new trials (Kerr 2018; HoEman 2015; Wichowicz 2017).
Included studies
From the first published version of this review, there were a
total of 12 included trials (14 interventions) (Creytens 1980; Dam
1996a/Dam 1996b; Forster 1996; Goldberg 1997; Grade 1998; House
2000; Palomaki 1999; RaEaele 1996; Rasmussen 2003; Reding 1986;
Robinson 2000a/Robinson 2000b; Roh 1996). We included two trials
in the 2008 update (Almeida 2006; Watkins 2007), resulting in 14
included trials (16 interventions), with 1515 participants at entry.
Two trials compared two active treatments with placebo (Dam
1996a; Robinson 2000a). We compared data from both treatment
arms in these trials with data from half the number of participants
in the control groups, and presented the results as two separate
studies (Dam 1996a/Dam 1996b; Robinson 2000a/Robinson 2000b).
One trial included an attention control (where the time participants
in the treatment group spent with a trained therapist was
controlled for by attention control participants spending equal
time with an untrained volunteer) as well as a control (usual
care) group (House 2000). We combined data from the attention
control and control group and compared these with data from
the treatment group. One trial (RaEaele 1996) included in the first
published version of the review (2004) is considered a 'dropout'
following closer inspection of the results as data was not available
for non-depressed participants only. More detailed information is
provided in the Characteristics of included studies table.
In this update, we included six new trials with 417 participants
(HoEman 2015; Kerr 2018; Robinson 2008; Tsai 2011; Wichowicz
2017; Xu 2006). In total, 19 trials (21 interventions) involving 1771
participants are included.
Participants
All trials in this review included men and women. The average age of
participants ranged from 55 to 73 years. Most of the trials reported
the time between stroke and randomisation into the trial, with
the range covering 'within three days' to six months. Most of the
trials included participants with ischaemic stroke, diagnosed using
a combination of standard clinical and computed tomography (CT)
criteria. For more detailed information on each included study,
please refer to the Characteristics of included studies table.
Interventions
Twelve trials (14 interventions) assessed pharmacological
interventions compared to placebo (Almeida 2006; Creytens 1980;
Dam 1996a/Dam 1996b; Grade 1998; Palomaki 1999; Rasmussen
2003; Reding 1986; Robinson 2000a/Robinson 2000b; Robinson
2008; Roh 1996; Tsai 2011; Xu 2006), and seven assessed
psychological interventions compared to usual care and/or
attention control (Forster 1996; Goldberg 1997; HoEman 2015;
House 2000; Kerr 2018; Watkins 2007; Wichowicz 2017). Results
from these trials are presented and discussed separately.
There were no trials reporting on the remaining comparisons:
(3) non-invasive brain stimulation and sham stimulation or
usual care; (4) pharmacological intervention and one of
various forms of psychological therapy versus pharmacological
intervention plus usual care and/or attention control; (5)
pharmacological intervention and one of various forms
of psychological therapy versus placebo plus psychological
therapy; (6) pharmacological intervention and non-invasive brain
stimulation versus pharmacological intervention plus sham
stimulation or usual care; (7) pharmacological intervention and
non-invasive brain stimulation versus placebo plus non-invasive
brain stimulation; (8) non-invasive brain stimulation and one
of various forms of psychological therapy versus non-invasive
brain stimulation plus usual care and/or attention control; and
(9) non-invasive brain stimulation and one of various forms of
psychological therapy versus sham brain stimulation or usual care
plus psychological therapy. (See Types of interventions).
Pharmacological interventions
Among trials of pharmacological interventions, six compared a
serotonin reuptake inhibitor (SSRI) against placebo (fluoxetine:
Dam 1996a; Robinson 2000a; sertraline: Almeida 2006; Rasmussen
2003; escitalopram: Robinson 2008), and paroxetine: Xu 2006),
one compared a serotonin antagonist and reuptake inhibitor
against placebo (trazodone: Reding 1986), one compared a tricyclic
antidepressant against placebo (nortriptyline: Robinson 2000b),
and one compared a serotonin-norepinephrine reuptake inhibitor
against placebo (milnacipran: Tsai 2011). Other treatments
with antidepressant eEects were used in five trials (piracetam:
Creytens 1980; maprotiline: Dam 1996b; mianserin: Palomaki 1999;
indeloxazine: Roh 1996), and a psychostimulant (methylphenidate:
Grade 1998). Four trials (five interventions) used a fixed dosing
regimen (Almeida 2006; Dam 1996a/Dam 1996b; Roh 1996; Xu
2006), and eight (nine interventions) used a flexible (Grade 1998;
Rasmussen 2003; Robinson 2008), or escalating (Creytens 1980;
Palomaki 1999; Reding 1986; Robinson 2000a/Robinson 2000b; Tsai
2011), regimen. Treatment duration varied from four weeks (Grade
1998; Reding 1986), to 52 weeks (Palomaki 1999; Rasmussen 2003;
Robinson 2008; Tsai 2011).
Psychological therapy
Varying forms of psychological therapy were used in the included
trials. Two trials stated explicitly that the intervention was
problem-solving therapy (Forster 1996; House 2000), or cognitive
behavioural coping therapy (HoEman 2015). Two trials provided
an intervention that was more broadly defined (home-based
therapy: Goldberg 1997; and solution-focused brief therapy:
Wichowicz 2017), and two provided motivational interviewing
(Kerr 2018; Watkins 2007). Five trials used 'usual care' as the
control comparison (Forster 1996; Goldberg 1997; HoEman 2015;
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Kerr 2018; Watkins 2007), and one used usual care and attention
control groups (House 2000). One trial stated that participants
in the control comparison did not receive any psychotherapeutic
interventions. The interventions were delivered by a variety of
trained professionals, including specialist nurses (Forster 1996;
HoEman 2015; House 2000; Kerr 2018; Watkins 2007; Wichowicz
2017), and a mixed team of therapists (Goldberg 1997; Watkins
2007). Treatment duration varied from one visit per week for




Thirteen assessment scales were used to diagnose the proportion
of people meeting the criteria for depression or scoring above
the cut-oE points for a depressive disorder in the 19 trials (21
interventions). The most commonly used measures were the
Hamilton Depression Rating Scale (Almeida 2006; Dam 1996a; Dam
1996b; Grade 1998; Palomaki 1999; Rasmussen 2003; Robinson
2000a; Robinson 2000b; Robinson 2008; Tsai 2011), and the Hospital
Anxiety Depression Scale (HoEman 2015; Kerr 2018; Wichowicz
2017). Seven trials used two or more scales to assess abnormal
mood or depression (Grade 1998; HoEman 2015; House 2000; Kerr
2018; Palomaki 1999; Rasmussen 2003; Watkins 2007), and two
older trials relied on a clinical or physician assessment (Reding
1986; Roh 1996).
Secondary outcomes
A variety of additional outcomes were assessed in each trial.
Several studies assessed and reported outcome data for depression
(Almeida 2006; Dam 1996a; Dam 1996b; Grade 1998; HoEman
2015; House 2000; Kerr 2018; Palomaki 1999; Rasmussen 2003;
Robinson 2000a/Robinson 2000b; Robinson 2008; Roh 1996; Tsai
2011; Watkins 2007; Wichowicz 2017; Xu 2006), psychological
distress (House 2000; Watkins 2007), general health (Forster 1996),
cognition (Almeida 2006; Grade 1998; Robinson 2000a/Robinson
2000b), social activities (Forster 1996; House 2000), activities of
daily living Dam 1996a/Dam 1996b; Forster 1996; HoEman 2015;
House 2000; Reding 1986; Watkins 2007; Xu 2006), disability
(Almeida 2006; Dam 1996a/Dam 1996b; Grade 1998; Robinson
2000a/Robinson 2000b), and anxiety (HoEman 2015; Kerr 2018;
Wichowicz 2017). A wide variety of additional measures were used
in the trials (see Characteristics of included studies). Although most
trials reported data from all the scales and assessments that were
stated as used, these data were o(en not presented in a format that
was easily collated for this review. We sought additional data from
study authors if possible. Adverse events were reported in many
studies (Almeida 2006; Creytens 1980; Dam 1996a/Dam 1996b;
Grade 1998; House 2000; Palomaki 1999; Robinson 2000a/Robinson
2000b; Robinson 2008; Roh 1996;Tsai 2011; Watkins 2007); however,
it was diEicult to determine whether recording and reporting of
adverse events were systematic. In other studies, adverse events
were not reported by randomised group (Reding 1986), or only in a
selected manner (Forster 1996; Goldberg 1997; Rasmussen 2003).
Ongoing studies
Two trials are ongoing (Sitzer 2002: pharmacological intervention;
Kirkevold 2018: psychological therapy).
Studies awaiting classification
From the previous published version of this review, there were
two trials listed as awaiting classification (Evans 1985; Katz 1998).
We were unable to obtain more information or outcome data
from these trials, despite multiple attempts to contact the study
authors. In the present review, there are four additional trials
listed as awaiting classification (Chang 2011; IRCT201112228490N1;
Ostwald 2014; Razazian 2016). We were unsure if depression was
the primary outcome in two trials (IRCT201112228490N1; Razazian
2016). In the other two trials, no information regarding supervision
was provided for the psychological therapy component of the
intervention to help us determine if they meet our review criteria
(Chang 2011; Ostwald 2014).
Dropout studies
In the previous published version of this review (Hackett 2008),
seven trials met the inclusion criteria but were considered
'dropouts' as data were not available for non-depressed
participants only (Downes 1995); or were either not available or not
in a suitable format for meta-analysis (Bramanti 1989; Friedland
1992; GraEingo 2003; Leathley 2003; McCaEerty 2000; Ohtomo
1985). See Table 1 for more detailed information on these trials.
We identified two new trials that met the inclusion criteria;
however, data were not available for non-depressed participants
only (Hadidi 2014; Kim 2017; Ostwald 2014). These trials are
considered 'dropouts' (Table 1). One trial (RaEaele 1996) previously
included in the first published version of the review (2004) is now
considered a 'dropout' following closer inspection of the results as
data was not available for non-depressed participants only.
We contacted the study authors of the dropout studies to request
data for non-depressed participants only. However, we did not
receive any responses.
Excluded studies
For this update, we excluded 17 trials at the full-text review stage.
Reasons for exclusion include: 1) depression was not the primary
outcome (n = 9); 2) unable to isolate data for stroke participants (n
= 3); 3) data were not available for non-depressed participants at
baseline (n = 2); 4) data were not available or in a suitable format
for pooling (n = 2) and; 5) participants were depressed at baseline
(n = 1). We have listed the excluded studies, and their reasons for
exclusion, in the Characteristics of excluded studies table.
Risk of bias in included studies
We present a graphical summary of 'Risk of bias' assessments
performed by review authors for the included studies, based on the
seven risk of bias domains (Figure 2). Figure 3 provides a summary
of risk of bias for each included study. The reasons for judgements
are provided in the 'Risk of bias' section in Characteristics of
included studies.
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Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Almeida 2006 + + + ? - ? ?
Creytens 1980 ? ? ? ? - ? ?
Dam 1996a ? ? ? + - ? +
Dam 1996b ? ? ? + - ? +
Forster 1996 ? ? ? ? - ? +
Goldberg 1997 + ? - - - ? +
Grade 1998 + + + + + ? +
Hoffman 2015 + ? - + + ? +
House 2000 + + - - + ? +
Kerr 2018 + - - - - ? +
Palomaki 1999 ? - + ? - ? ?
Rasmussen 2003 ? ? + + - ? ?
Reding 1986 + ? + + - ? +
Robinson 2000a ? ? + + - ? +
Robinson 2000b ? ? + + - ? +
Robinson 2008 + + + + + - +
Roh 1996 + + + + - ? +
Tsai 2011 ? + + + + + ?
Watkins 2007 ? - - - + ? +
Wichowicz 2017 + ? - + + ? +
Xu 2006 ? ? ? ? ? ? +
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Allocation
The randomisation sequence was appropriately generated in 10
trials (Almeida 2006; Goldberg 1997; Grade 1998; HoEman 2015;
House 2000; Kerr 2018; Reding 1986; Robinson 2008; Roh 1996;
Wichowicz 2017), thus we rated these as low risk. However, nine
trials (11 interventions) did not describe their method of sequence
generation; we rated these as unclear risk (Creytens 1980; Dam
1996a/Dam 1996b; Forster 1996; Palomaki 1999; Rasmussen 2003;
Robinson 2000a/Robinson 2000b; Tsai 2011; Watkins 2007; Xu
2006).
We rated six trials as low risk as an appropriately generated and
clearly concealed allocation procedure was used (Almeida 2006;
Grade 1998; House 2000; Robinson 2008; Roh 1996; Tsai 2011).
Twelve trials (10 interventions) did not describe their method
of allocation concealment and so we rated them as unclear risk
(Creytens 1980; Dam 1996a/Dam 1996b; Forster 1996; Goldberg
1997; HoEman 2015; Rasmussen 2003; Reding 1986; Robinson
2000a/Robinson 2000b; Wichowicz 2017; Xu 2006). One trial used
opaque sealed envelopes (Watkins 2007), while another trial used
coloured paper to conceal allocation (Kerr 2018), and one trial
used sealed envelopes as their method of allocation concealment
(Palomaki 1999), so they were all rated as high risk.
Blinding
Nine trials (10 interventions) reported that participants and
personnel were blinded to the treatment allocation and so we
rated these as low risk (Almeida 2006; Grade 1998; Palomaki 1999;
Rasmussen 2003; Reding 1986; Robinson 2000a/Robinson 2000b;
Robinson 2008; Roh 1996; Tsai 2011). Four trials (five interventions)
did not provide information about blinding of participants and
personnel so we rated them as unclear risk (Creytens 1980; Dam
1996a/Dam 1996b; Forster 1996; Xu 2006). We rated six trials as high
risk (Goldberg 1997; HoEman 2015; House 2000; Kerr 2018; Watkins
2007; Wichowicz 2017): due to the nature of the intervention in
these trials, it is very unlikely that the participants and personnel
remained blinded to the treatment allocation.
We rated nine trials (11 interventions) as low risk as outcome
assessors were blinded to the treatment allocation (Dam
1996a/Dam 1996b; Grade 1998; HoEman 2015; Rasmussen 2003;
Robinson 2000a/Robinson 2000b; Robinson 2008; Roh 1996; Tsai
2011; Wichowicz 2017). Five trials did not provide information
about blinding of outcome assessors and so we rated them as
unclear risk (Almeida 2006; Creytens 1980; Forster 1996; Palomaki
1999; Xu 2006). Three trials had blinded outcome assessors,
however it is likely that they became aware of the treatment
allocation and we therefore rated them as high risk (Goldberg
1997; House 2000; Kerr 2018). In one trial, participants were sent
questionnaires to complete on their own and so we also rated this
as high risk (Watkins 2007).
Incomplete outcome data
We rated seven trials as low risk as they provided intention-
ti-treat (ITT) analyses (Grade 1998; HoEman 2015; House 2000;
Robinson 2008; Tsai 2011; Watkins 2007; Wichowicz 2017). One
trial reported completing ITT analyses but not how they handled
missing data so we rated it as unclear risk (Xu 2006). We rated
11 trials (13 interventions) as high risk for attrition bias as
they reported per-protocol analyses only (Almeida 2006; Creytens
1980; Dam 1996a/Dam 1996b; Forster 1996; Goldberg 1997; Kerr
2018; Palomaki 1999; Rasmussen 2003; Reding 1986; Robinson
2000a/Robinson 2000b; Roh 1996).
Selective reporting
We rated one trial as low risk as all pre-specified outcomes from
the trial protocol were reported in the publication (Tsai 2011). We
rated 17 trials (19 interventions) as unclear risk as all pre-specified
outcomes were reported but no trial protocol was available to
compare with the publication (Almeida 2006; Creytens 1980; Dam
1996a/Dam 1996b; Forster 1996; Goldberg 1997; Grade 1998;
HoEman 2015; House 2000; Kerr 2018; Palomaki 1999; Rasmussen
2003; Reding 1986; Robinson 2000a/Robinson 2000b; Roh 1996;
Watkins 2007; Wichowicz 2017; Xu 2006). We rated one trial as
high risk as one outcome reported in the study protocol or trial
registry information page was not reported in the primary results
publication (Robinson 2008).
Other potential sources of bias
We rated 14 trials (16 interventions) as low risk as the baseline
demographic characteristics were balanced between the groups
(Dam 1996a/Dam 1996b; Forster 1996; Goldberg 1997; Grade 1998;
HoEman 2015; House 2000; Kerr 2018; Reding 1986; Robinson
2000a/Robinson 2000b; Robinson 2008; Roh 1996; Watkins 2007;
Wichowicz 2017; Xu 2006). We rated five trials as unclear risk
as either no information about baseline demographics between
groups were provided or we were unclear how diEerences in age or
the proportion of participants with heart disease in one group may
pose bias (Almeida 2006; Creytens 1980; Palomaki 1999; Rasmussen
2003; Tsai 2011).
E;ects of interventions
See: Summary of findings 1 Pharmacological interventions
(antidepressants) compared to placebo for preventing depression
a(er stroke; Summary of findings 2 Psychological therapy
compared to usual care and/or attention control for preventing
depression a(er stroke
See 'Summary of findings 1; Summary of findings 2'.
Overall, we included 1930 participants in this review. In view of the
large number and heterogeneous nature of the outcome measures
and the reporting of results, we considered it inappropriate to pool
outcome data for many endpoints. For details of the comparisons
made for the studies with outcome data, refer to the Data and
analyses section (as outlined in the protocol, data for trials of
psychostimulants (Grade 1998) are presented separately).
Primary outcome
Depression
Meeting the study criteria for depression at the end of treatment
Eight trials, nine pharmacological interventions, found favourable
treatment eEects (risk ratio (RR) 0.50, 95% confidence interval
(CI) 0.37 to 0.68, 734 participants, very low-certainty evidence,
Analysis 1.1) for this outcome at the end of treatment compared to
placebo (Almeida 2006; Palomaki 1999; Rasmussen 2003; Robinson
2000a/Robinson 2000b; Robinson 2008; Roh 1996; Tsai 2011; Xu
2006). No heterogeneity was observed but confidence intervals
were very wide.
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Two trials of psychological therapy revealed favourable treatment
eEects (RR 0.68, 95% CI 0.49 to 0.94, 607 participants, very low-
certainty evidence, Analysis 2.1) for this outcome at the end
of treatment compared to usual care and/or attention control
(House 2000; Watkins 2007). No heterogeneity was observed but
confidence intervals were very wide.
Other outcomes
Depression
Average change in scores between baseline and end of treatment
Three trials, five pharmacological interventions, found no
statistically significant diEerence in the average change in
depression scores between baseline and the end of treatment
between those who received pharmacological interventions
compared to placebo (standardised mean diEerence (SMD) -0.05,
95% CI -0.33 to 0.23, 211 participants, Analysis 1.3) (Almeida 2006;
Dam 1996a/Dam 1996b; Robinson 2000a/Robinson 2000b). No
heterogeneity was observed but confidence intervals were very
wide.
We did not perform a meta-analysis for the comparison between
psychostimulants and placebo (Analysis 3.1), as only one trial
contributed data to this outcome (Grade 1998).
Mean scores at the end of treatment
Two trials, four pharmacological interventions, revealed no
statistically significant diEerence in mean depression scores at the
end of treatment between the pharmacological intervention and
placebo groups (MD 0.59, 95% CI -1.46 to 2.63, 100 participants,
very low-certainty evidence, Analysis 1.4) (Dam 1996a/Dam 1996b;
Robinson 2000a/Robinson 2000b). No heterogeneity was observed
but confidence intervals were very wide.
We did not perform a meta-analysis on this outcome for the
comparison psychological therapy versus usual care and/or
attention control (Analysis 2.3), due to the heterogenous nature of
the outcome measures.
Mean scores at the end of follow-up
We did not perform a meta-analysis on this outcome for the
comparison: psychological therapy versus usual care and/or
attention control (Analysis 2.4), due to the heterogenous nature of
the outcome measures.
Psychological distress
Two trials of psychological therapy found favourable treatment
eEects in the average change in psychological distress scores
between baseline and the end of treatment (MD -1.37, 95% CI -2.27
to -0.48, 607 participants, Analysis 2.5) compared to usual care or
attention control (House 2000; Watkins 2007). No heterogeneity
was observed but confidence intervals were very wide.
We did not perform a meta-analysis on the mean psychological
distress scores at the end of treatment for the comparison
psychological therapy versus usual care and/or attention control
(Analysis 2.6), due to the heterogenous nature of the outcome
measures.
General health
We did not perform a meta-analysis on the average change
and mean general health scores at the end of treatment for
the comparison psychological therapy versus usual care and/
or attention control (Analysis 2.7; Analysis 2.8), due to the
heterogenous nature of the outcome measures.
Cognition
Average change in scores between baseline and end of treatment
Two trials, three pharmacological interventions, found no
statistically significant diEerence between the pharmacological
intervention and placebo groups at the end of treatment (MD 0.11,
95% CI -1.02 to 1.24, 159 participants, very low-certainty evidence
Analysis 1.5) (Almeida 2006; Robinson 2000a/Robinson 2000b). No
heterogeneity was observed but confidence intervals were very
wide.
We did not perform a meta-analysis on this outcome for
the comparison pharmacological interventions versus placebo
(psychostimulants) as only one study contributed data to this
outcome (Analysis 3.2).
Mean scores at the end of treatment
One trial, two pharmacological interventions, revealed no
statistically significant diEerence between the pharmacological
intervention and placebo groups at the end of treatment (MD
-0.42, 95% CI -2.60 to 1.76, 48 participants, Analysis 1.6) (Robinson
2000a/Robinson 2000b). No heterogeneity was observed but
confidence intervals were very wide.
Social activities
Two trials of psychological therapy found no statistically significant
diEerence between the psychological therapy and usual care and/
or attention control groups at the end of treatment (MD -0.39, 95%
CI -3.81 to 3.03, 690 participants, Analysis 2.10) (Forster 1996; House
2000). There was 80% heterogeneity and very wide confidence
intervals.
Activities of daily living
Average change in scores between baseline and end of treatment
Two trials, three pharmacological interventions, found no
statistically significant diEerence between the pharmacological
intervention and placebo groups at the end of treatment (MD 1.18,
95% CI -7.77 to 10.14, 57 participants, very low-certainty evidence,
Analysis 1.7) (Dam 1996a/Dam 1996b; Reding 1986).
Three trials of psychological therapy revealed no statistically
significant diEerence between the psychological therapy and usual
care and/or attention control groups at the end of treatment (MD
0.29, 95% CI -0.18 to 0.77, 847 participants, very low-certainty
evidence, Analysis 2.11) (Forster 1996; House 2000; Watkins 2007).
Mean scores at the end of treatment/follow-up
Two trials, three pharmacological interventions, found no
favourable treatment eEects compared to placebo (MD -3.86, 95%
CI -9.48 to 1.77, 116 participants, Analysis 1.8) (Dam 1996a/Dam
1996b; Xu 2006). There was minimal heterogeneity (I2 = 22%) and
very wide confidence intervals were observed.
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We did not perform a meta-analysis on this outcome for
the comparison psychological therapy versus usual care and/
or attention control (Analysis 2.12; Analysis 2.13), due to the
heterogenous nature of the outcome measures.
Disability
We did not perform a meta-analysis on this outcome for
the comparison pharmacological interventions versus placebo
(antidepressants) (Analysis 1.9; Analysis 1.10), due to the
heterogenous nature of the outcome measures.
We did not perform a meta-analysis on this comparison of
pharmacological interventions versus placebo (psychostimulants),
as only one trial contributed data to this outcome (Analysis 3.3).
Anxiety
We did not perform a meta-analysis on this outcome for
the comparison psychological therapy versus usual care and/
or attention control (Analysis 2.14; Analysis 2.15), due to the
heterogenous nature of the outcome measures.
Adverse events: death
Eight trials, nine pharmacological interventions found no
statistically significant diEerence in death between those who
received pharmacological interventions compared to placebo (RR
1.25, 95% CI 0.32 to 4.91, 496 participants, very low-certainty
evidence, Analysis 1.12) (Creytens 1980; Dam 1996a/Dam 1996b;
Palomaki 1999; Robinson 2000a/Robinson 2000b; Robinson 2008;
Roh 1996; Xu 2006). No heterogeneity was observed but confidence
intervals were very wide.
Five trials of psychological therapy showed no statistically
significant diEerence between the psychological therapy and
usual care and/or attention control groups. No heterogeneity was
observed but confidence intervals were very wide (RR 1.18, 95%
CI 0.73 to 1.91, 975 participants, very low-certainty evidence,
Analysis 2.16) (Forster 1996; House 2000; Kerr 2018; Watkins 2007;
Wichowicz 2017).
Adverse events: all
There was no statistically significant harm in the pharmacological
interventions versus placebo (antidepressants) or psychological
therapy versus usual care and/or attention control comparisons.
See Analysis 1.13; Analysis 2.17. One trial reported that
psychostimulants resulted in no deaths at the end of treatment
(Analysis 3.4).
Adverse events: leaving the study early (including death)
Ten trials, 12 pharmacological interventions, found no statistically
significant diEerence between the pharmacological interventions
and placebo groups at the end of treatment (RR 1.03, 95% CI 0.84 to
1.26, 836 participants, Analysis 1.14) (Almeida 2006; Creytens 1980;
Dam 1996a/Dam 1996b; Palomaki 1999; Rasmussen 2003; Robinson
2000a/Robinson 2000b; Robinson 2008; Roh 1996; Tsai 2011; Xu
2006). No heterogeneity was observed but confidence intervals
were very wide.
We did not perform a meta-analysis on this outcome for
the comparison pharmacological interventions versus placebo
(psychostimulants), as only one trial contributed data to this
outcome (Analysis 3.5).
Six trials of psychological therapy revealed no statistically
significant diEerence between the psychological therapy and usual
care and/or attention control groups (RR 1.30, 95% CI 0.90 to
1.88, 1030 participants, Analysis 2.18) (Forster 1996; Goldberg
1997; House 2000; Kerr 2018; Watkins 2007; Wichowicz 2017). No
heterogeneity was observed but confidence intervals were very
wide.
D I S C U S S I O N
Summary of main results
We added six new trials (417 participants) to this review update,
resulting in 19 included trials (21 interventions, 1771 participants).
Data were available for 12 pharmacological trials (14 interventions)
and seven psychological trials. We found no trials of other included
interventions, or their combination.
Pharmacological therapy trials
Compared with placebo, there is very low-certainty evidence which
shows that pharmacological therapy reduced the incidence of
depression a(er stroke. The very low-certainty rating was due to
the variety of study methods and endpoints measured, inadequate
reporting of allocation concealment, evidence of attrition bias (high
numbers of dropouts in several of the studies), and wide confidence
intervals. Because of this low certainty we have previously only
provided a narrative review of data for pharmacological therapy
and concluded that the evidence did not indicate that it was
eEective in preventing depression a(er stroke (Hackett 2008). In
other non-stroke trials, where antidepressants did not result in a
clinically significant reduction in depressive symptoms, benefits
were indicated on other emotional symptoms, such as reducing
anxiety and improving self-rated mental health and quality of life
(e.g. Lewis 2019). There was no evidence of adverse eEects or death
associated with the use of pharmacological therapy to prevent
depression a(er stroke. However, important known adverse eEects
such as falls and hip fracture apparent in other stroke trials (FOCUS
2019), were not reported, or the included trials were too small to
identify them or, most likely, they were not systematically recorded.
The pharmacological therapy trials included participants whose
time from onset of stroke to randomisation ranged from within
three days to 13 weeks. Duration of the interventions ranged from
three weeks to 52 weeks. This is important because of the serious
debate about withdrawal eEects and uncertainty about the balance
of risk and benefit in longer-term prescribing. The prescription
of antidepressants in this population is usually started in stroke
services and maintained in primary care. This means important
uncertainty remains for service providers and the evidence on
which to guide pharmacological therapy is limited.
Psychological therapy trials
Compared to usual care or attention control, there is very
low-certainty evidence which shows that psychological therapy
reduced the incidence of depression a(er stroke at the end of
treatment. No new trials reported on this outcome so these
results are the same as in the previous review (Hackett 2008).
As for pharmacological therapy, potential minor benefits on non-
specific symptoms are not covered. The certainty of evidence was
very low due to inadequate reporting of allocation concealment
and blinding of participants, personnel and outcome assessment,
evidence of attrition bias (high numbers of dropouts in several of
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the studies), and wide confidence intervals. There was no evidence
of adverse eEects or death associated with psychological therapy
to prevent depression a(er stroke.
Psychological therapy trials included participants whose time from
onset of stroke to randomisation ranged from within days to 30
weeks. It is diEicult to consider trials including participants six
months a(er their stroke as true prevention trials. Duration of
treatment was between four weeks and 52 weeks.
Non-invasive brain stimulation or combinations of included
intervention trials
We found no trials of non-invasive brain stimulation compared with
sham stimulation or usual care, or a combination of any of the
included interventions with only one of the included interventions,
to prevent depression a(er stroke.
Other trials
There were 10 trials we considered as 'dropouts' as outcome data
were not analysed by depression status at baseline (n = 4) or
not in a suitable format for pooling (n = 6). There are six trials
awaiting classification. We were unable to obtain more information
or outcome data in two trials. We were unsure if depression was
the primary outcome in two trials, and in three trials we were
unable to determine if the psychological therapy component meets
the review criteria. Two ongoing trials (one psychological and one
pharmacological therapy) will contribute more evidence for future
updates of this review. The identification of ongoing trials, dropout
trials, and trials awaiting classification indicate that this is an area
of research for which further evidence will evolve in the short and
longer term.
A major but not unexpected finding was the considerable
heterogeneity in design, analysis, and reporting of clinical trials
in this area of stroke medicine. To begin with, the trials included
participants whose time from the onset of stroke to randomisation
ranged from several days to seven months. It is likely that the
aetiology of depression and response to treatment will vary across
the diEerent stages of recovery from stroke; for example, people
who are in the acute phase of stroke are likely to be adjusting to
experiencing a potentially life-threatening event as well as rapidly
evolving eEects of cerebral ischaemia. On the other hand, those
who survive long term are adjusting to any fixed neurological
deficits and residual disability, with varying impact on their social
and financial situation. In a similar manner, the eEects of treatment
are likely to vary according to whether they are administered for
short (several weeks) or long (several months to a year) time
periods.
Another aspect of heterogeneity was the inclusion criteria
across trials. Ideally, participants should be homogeneous with
regard to stroke diagnosis, which requires the use of standard
diagnostic criteria and neuroimaging in a high proportion of
cases. Several of the pharmacological therapy trials, and only
one of the psychological therapy trials, reported the method
used to diagnose stroke, and while most did not provide details
regarding stroke subtype, four trials included participants with
subarachnoid haemorrhage. Given diEerences in the natural
history, management, and also potential aetiological factors for
depression in the setting of subarachnoid haemorrhage, it could be
argued that this form of stroke should be examined separately to
atherosclerotic stroke.
With regard to other entry criteria, many trials excluded
people with communication problems, cognitive impairment, and
previous psychiatric illness. This may be appropriate for trials
of psychological therapy, as participants are required to engage
actively in talking therapies. However, use of a large list of
exclusions in trials of pharmacological therapy means that the
results are likely to be applicable only to a small proportion of
survivors of stroke who have a narrow range of co-morbidity
and other characteristics. This reinforces a common criticism
of depression research in the general population that the trial
participants are not representative of those requiring treatment
in the 'real world' (Zimmerman 2002). It would appear that this
criticism is also applicable to trials to prevent depression a(er
stroke, where up to half of survivors may be excluded using
such criteria (Turner-Stokes 2003). Given the older age of most
people with stroke, and the frequent presence of neurological
impairments, aphasia, and co-morbid medical conditions, the fact
that up to half of survivors are excluded from these trials limits the
external validity of the results.
While it is relatively easy to diagnose major vascular disease
endpoints in clinical trials, defining depression as an outcome
can be problematic. Disturbances of language and cognition
are common a(er stroke, and physical and other behavioural
cues, such as slowness, reduced appetite, and loss of facial
expression, may be misleading in the diagnosis of abnormal mood.
Although gold-standard diagnostic definitions are available for
major depression, dysthymia (Persistent Depressive Disorder) and
other mood disorders (for example, APA 1987, APA 1994, APA 2013,
and ICD 10 1992), these require modification to use among people
with stroke. Clearly, there is the need to accept stroke as the
concomitant medical condition, but also the presence of symptoms
for less than the two years required for a diagnosis of dysthymia. In
this situation minor depression (APA 1994), which is characterised
by the presence of two to four depressive symptoms during a two-
week period, and requires one of these symptoms to be either
depressed mood or loss of interest or pleasure, may be more
appropriate.
In clinical practice, a trained health professional establishes
the presence of abnormal mood by interviewing a person.
Given the practical diEiculties and high cost of conducting
detailed psychiatric interviews on participants in clinical trials,
we considered it appropriate to adopt a pragmatic approach and
determine a case of depression on the basis of a psychiatric
interview or use of a validated mood questionnaire. However,
there are several problems associated with this approach. First,
some studies included participants whose baseline mood scores
were within the range for abnormal mood or depression. As we
consider it inappropriate to undertake a study of the prevention
of depression when it may already be present, we have elected
to exclude these participants in these studies until data are
available from the researchers. Second, the multiple approaches
and scales used to assess mood across studies, and the variation
in reporting of data within and between studies, made the pooling
of data inappropriate in most cases. Finally, since primary a priori
endpoints were seldom reported for the multiple measures used,
it was diEicult to assess whether the data presented were truly the
intended primary outcomes in many studies, particularly given the
high number of studies with selective reporting of outcomes.
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Another important aspect of trial design is the sample size required
to detect a clinically meaningful eEect; that is, how much of a
diEerence between groups is considered reasonable to expect.
While the continuous measures oEered by various mood scales are
appealing, as only 50 to a few hundred participants may be required
in trials, the clinical significance of a few points diEerence between
group means on follow-up is not so clear cut. Transformation of
scores according to particular cut-oE values, or the assessment of
people using standardised clinical diagnostic criteria to provide a
categorical disease endpoint is more meaningful, but may require
several thousand participants. In addition, participants in clinical
trials are likely to be more biologically robust and may potentially
receive a treatment eEect by virtue of their participation alone.
Finally, it is diEicult to interpret the significance of outcomes
when there is inadequate concealment of randomisation and
high numbers of dropouts in several of the studies. Few trials
systematically recorded and reported adverse events, making it
impossible to undertake a reliable assessment of the benefits and
risks of therapy. There was inconsistency in the methods of analysis
and reporting of results, with most studies presenting per-protocol
analyses. For trials with high dropouts (more than 20%), intention-
to-treat (ITT) analysis becomes very important. Should ITT (with
missing data for the best possible and worst possible outcome) and
per-protocol analyses indicate similar trends, then the findings are
likely to be interpreted as clinically robust.
In summary, the lack of evidence of an eEect of pharmacological
and psychological therapy for preventing depression a(er stroke
can be readily attributed to the limited numbers of studies, many of
which are limited by poor study design, analysis, and reporting, as
much as to the possible lack of limited eEicacy of the interventions.
Overall completeness and applicability of evidence
The present review included 19 trials (21 interventions), with
1771 participants. Data were available for 12 pharmacological
trials (14 interventions) and seven psychological therapy trials.
We considered 11 trials as 'dropouts' as outcome data were not
available in a suitable format for the review (six trials), or were
not presented by depressed and not depressed participants at
baseline (five trials). Five trials (two pharmacological interventions
and three psychological therapies) are awaiting classification Two
trials (pharmacological interventions and psychological therapy)
are ongoing.
The accuracy of the findings of this systematic review and meta-
analysis is based on the trials which met the eligibility criteria.
These findings must be considered in light of several basic
methodological limitations of many of these trials, including the
short duration of many interventions, variation in the types of trial
participants recruited, the methods used to diagnose depression,
lack of an a priori measurable endpoint, and the generally poor
design, outcome assessment, analysis and interpretation of results.
We will incorporate new data in future updates.
Quality of the evidence
We rated the certainty of evidence for all comparisons using the
five GRADE considerations (study limitations, consistency of eEect,
indirectness, imprecision and publication bias; Schünemann 2019).
We created a 'Summary of findings' table for each comparison.
Overall, we assessed the certainty as very low.
Limitations in study design or execution
For the comparison of pharmacological interventions with placebo,
we downgraded the certainty of evidence for the following
outcomes: meeting the study criteria for depression at end of
treatment, mean depression scores, mean cognition scores, mean
activities of daily living scores, and death at end of treatment by two
points as we rated several trials as having a high or unclear risk of
bias in multiple domains. See Summary of findings 1.
For the comparison of psychological interventions with usual
care and/or attention control, we downgraded the certainty of
evidence for the following outcomes: meeting the study criteria for
depression at end of treatment, mean social activities scores, and
death at end of treatment by two points as we rated several trials
as having a high risk in multiple risk of bias domains. See Summary
of findings 2.
Inconsistency of results
For the comparisons of pharmacological interventions with
placebo, we did not downgrade the certainty of evidence for
inconsistency of results. No heterogeneity between the studies was
observed. See Summary of findings 1;
For the comparison of psychological therapy with usual care and/
or attention control, we downgraded the social activities scores by
two points for substantial heterogeneity (I2 = 80%). See Summary
of findings 2.
Indirectness of evidence
All included trials addressed the main review questions (PICO): 1)
the eEect of pharmacological interventions compared to placebo;
and 2) psychological therapy compared to usual care and/or
attention control in preventing depression or depressive symptoms
a(er stroke. Thus, we did not downgrade any outcomes in any
comparisons for indirectness of evidence. See Summary of findings
1; Summary of findings 2.
Imprecision
For the comparison of pharmacological interventions with placebo,
we downgraded the certainty of evidence for meeting the study
criteria for depression at the end of treatment by one point because
the confidence intervals were wide. We also downgraded the
certainty of evidence for the following outcomes: mean depression
scores, mean cognition scores, mean activities of daily living scores,
and death at end of treatment, because the confidence intervals
were very wide. See Summary of findings 1.
For the comparison of psychological interventions with usual care
and/or attention control, we downgraded the certainty of evidence
for meeting the study criteria for depression at end of treatment
by one point because the confidence intervals were wide. We also
downgraded the certainty of evidence for the following outcomes:
mean social activities score and death at end of treatment, because
the confidence intervals were very wide. See Summary of findings
2.
Publication bias
We assessed publication bias using funnel plots for the outcome:
meeting the study criteria for depression at end of treatment for
the pharmacological interventions versus placebo comparison. We
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deemed this necessary to show no evidence of publication bias for
this outcome (Figure 4), as there were nine trials (close to 10 trials,
the usual minimum requirement) contributing to the analysis. We
did not assess publication bias using funnel plots for the other
outcomes due to the small number of trials (< 10 trials) contributing
to the analysis. Therefore, we did not downgrade the certainty of
evidence for publication bias in any of the outcomes. See Summary
of findings 1; Summary of findings 2.
 
Figure 4.   Funnel plot of comparison: 1 Pharmacological interventions (antidepressants) versus placebo, outcome:
1.1 Depression: meeting study criteria for depression at end treatment.









CGI (high score = more severe)
Clinician interview/impression (no improvement)
Meets DSM-III-R criteria
Meets DSM-IV criteria
HADS (high score = more severe)
HDRS (high score = more depressed)
 
Potential biases in the review process
Strengths and weaknesses of this review
This review has rigorously adhered to the Cochrane methods for
performing systematic reviews. During the review process we have
tried to avoid and minimise any biases. We undertook extensive
searches of databases and additional resources. We did not apply
any language restrictions within the search process. Thus, we
believe that we have identified and included all potentially relevant
trials in this review. We arranged for any potentially relevant non-
English full-text trials to be translated into English to finalise
the eligibility process. Furthermore, at least two review authors
independently extracted and managed the data.
The main weakness of this review is the heterogenous nature of the
outcome measures and the frequent use of multiple scales between
and within trials. As a result, we were unable to pool outcome data
for many endpoints. Furthermore, inadequate reporting for some
of the trials has precluded classification of risk of bias as either low
or high risk. This has led us to rate some of the trials across the
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categories as having an unclear risk of bias and an overall rating of
'very low' certainty of evidence.
Agreements and disagreements with other studies or
reviews
To date, there are no other systematic reviews as comprehensive as
the current review.
We found one other systematic review comparing the eEect of
pharmacotherapy to prevent depression in the stroke population
(Salter 2013). This review is similar to our review, particularly in
their inclusion of trials with people with no diagnosed depressive
disorder or a mood score below the standard cut-oE score for a
depressive disorder at baseline. The authors included eight trials,
of which six trials (seven interventions) (Almeida 2006; Palomaki
1999; Rasmussen 2003; Robinson 2000a/Robinson 2000b; Robinson
2008; Tsai 2011) are included in our review. In contrast to our review,
that review combined the results from both active treatment
conditions/arms (nortriptyline and fluoxetine) from the Robinson
2000a trial in their analysis. We excluded the other two included
trials as one trial did not have a placebo comparison and the other
trial had motor function as the primary outcome. The Salter 2013
review found a significant reduced risk for depression (odds ratio
(OR 0.34, 95% CI 0.22 to 0.53) based on satisfactory methodological
quality according to the Jadad scale (Clark 1999). Similarly, they
also found that the reporting of adverse events was generally
poor, making it diEicult to undertake a reliable and meaningful
evaluation of the relative risks for adverse events associated with
prophylactic therapy.
We found a more targeted systematic review of fluoxetine to
prevent depression in the stroke population (Yi 2010). Only two
of their six included trials are included in our review (Dam
1996a; Robinson 2000a) . We excluded the remaining four of
their included trials as they did not have a placebo comparison.
Yi 2010 demonstrated that fluoxetine reduced the incidence of
depression a(er stroke (OR = 0.25, 95% CI 0.11 to 0.56), with no
evidence of adverse events (OR) 0.88, 95% CI 0.31 to 2.49, P = 0.82).
The authors noted several methodological limitations including
inadequate randomisation sequence, randomisation concealment,
and dropout rates ranging from 0% to 11.1% in the fluoxetine
groups and from 0% to 14.3% in the control groups.
There were no systematic reviews comparing the eEect of repetitive
transcranial magnetic stimulation (rTMS) to sham rTMS, or of a
combination of rTMS and pharmacotherapy to usual care or sham
rTMS and pharmacotherapy to prevent depression a(er stroke.
There is one systematic review evaluating the use of rTMS in
people diagnosed with major depressive disorder in the general
populations rather than a population with stroke (Rachid 2018).
However, rTMS was not used to prevent depression but more as
maintenance therapy to prevent relapse of depression.
One systematic review reported on the eEect of psychotherapy
for preventing depression a(er stroke (Baker 2018). The authors
included five trials, of which one (HoEman 2015), is included in our
review. We excluded the remaining four trials as the intervention
in two did not meet the review criteria, one trial only included
caregivers, and the remaining trial did not have depression as the
primary outcome. The review authors did not perform a meta-
analysis and only described the included studies narratively .
The identification of studies currently ongoing and those awaiting
classification indicate that this is an area of stroke research for
which further evidence will evolve in the short and longer term.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is inadequate evidence at present to support the
routine use of antidepressants, psychostimulants, other drugs,
or psychological therapies to prevent depression and improve
recovery a(er stroke. All positive eEects are based on very low-
certainty evidence. The small positive benefit of psychological
strategies probably endorses the use of more structured
approaches to the delivery of education and advice targeting
emotional recovery and adjustment to the eEects of stroke.
However, the amount of evidence to support the routine use
of these approaches in stroke rehabilitation is limited, as is the
generalisability of these findings to all stroke survivors due to the
narrow inclusion and exclusion criteria for participants in these
trials.
Implications for research
One reason for uncertainty in this area is that previous trials
have been of inadequate design. There is a need for further
research using more rigorous methods. In addition to concealment
of randomisation, and blinded treatment allocation and outcome
assessments, future trials of pharmacological and psychological
therapy for the prevention of depression a(er stroke should be
designed with attention to the methodological issues described
below.
• The trial should be of adequate power to detect modest but
clinically important eEects on a binary endpoint of significantly
abnormal mood state, defined either by structured psychiatric
interview or a validated mood scale.
• Participants should be recruited early (within four to six weeks)
a(er the onset of stroke and the treatment continued for at
least six months (the high-risk period), to allow the maximum
eEect on the natural history of the disorder and evaluation of a
treatment regimen that could be relatively easily adopted into
clinical practice.
• Standard clinical criteria for stroke should be used, and
people with subarachnoid haemorrhage and those depressed at
baseline excluded from participation.
• Exclusion criteria should be kept to a minimum without forgoing
safety to allow trial results to be generalisable to most stroke
survivors.
• A priori primary and secondary outcomes should be stated.
• Careful prospective assessment and complete reporting of
adverse events should be undertaken.
• A limited number of key outcomes should be measured and
reported.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: parallel design
Number of arms: 2
Treatment arm: sertraline (SSRI)
Control arm: matched placebo
Participants Geographical location: Australia
Setting: inpatient
Stroke criteria: acute ischaemic or haemorrhagic stroke
Method of stroke diagnosis: via clinical signs (ICD-10) and CT (100% imaged, 10/111 CT scan did not
show acute ischaemia)
Time since stroke: stroke on average < 2 weeks prior to randomisation
Inclusion criteria: not reported
Almeida 2006 
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Exclusion criteria: 1) severe communication difficulties; 2) unstable medical condition; 3) severe cogni-
tive impairment and depression; 4) taking antidepressants within 4 weeks of stroke; 5) contraindication
to sertraline
Depression criteria: HADS score > 8
Total number randomised in this trial: 111
Number randomised to treatment group: 55 (67% men, mean age 68 years, SD 13)
Number randomised to control group: 56 (62% men, mean age 67 years, SD 13)
Total number included in the final analysis: 99
Number included in treatment group for final analysis: 48
Number included in control group for final analysis: 51
Interventions Treatment: sertraline (SSRI), 50 mg, daily (night)
Control: matched placebo
Treatment duration: treatment continued for 24 weeks
Follow-up: 28 weeks post treatment end (52 weeks from baseline)
Outcomes Primary outcomes
• Depression measured using the HDRS
Secondary outcomes
• Cognitive function measured using the MMSE
• Disability measured using the mRS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Subjects were allocated to 24-week treatment with placebo or sertra-
line (fixed daily dose of 50mg at night) according to a computer-generated ran-
dom list of numbers ..." pp. 1105
Allocation concealment
(selection bias)
Low risk Quote: "Placebo and sertraline were delivered in capsules that had the same





Low risk Quote: "Both the research team and participants were unaware of treatment
allocation …" pp. 1105
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk Quote: "... last observation carried forward (LOCF) analyses to investigate the
primary endpoint of interest for this study ..." pp. 1106
Comments: per protocol analysis presented. 11/111 were not included in the
analysis
Almeida 2006  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Unclear risk Comments: more participants in treatment group with previous heart attack





Methods Study design: parallel design
Number of arms: 2
Experimental arm: piracetam (nootropic agent)
Control arm: matched placebo
Participants Geographical location: Belgium
Setting: inpatient (women's hospital)
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical signs
Time since stroke: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Total number randomised in this trial: 50
Number randomised to treatment group: 25 (0% men, mean age 73 years SD not reported)
Number randomised to control group: 25 (0% men, mean age 69 years SD not reported)
Total number included in final analysis: 42
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: piracetam (nootropic agent), 6g IM daily for 7 days, 4.8 g (4 x 400 mg three times a day oral-
ly) daily for 30 days
Control: matched placebo
Treatment duration: treatment continued for 37 days
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the BOP scale (depressive behaviour sub scale)
Secondary outcomes
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Two independent groups of patients suffering a CVA (acute stage)
were randomized…." pp. 23
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Quote: "This study was double-blind." pp. 23
Comments: no details of who was blinded was reported
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "This study was double-blind." pp. 23




High risk Comments: per protocol analysis presented only. 8/50 participants were not
included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: Italy
Setting: unclear
Stroke criteria: ischaemic, unilateral MCA territory stroke
Method of stroke diagnosis: via clinical signs and CT (100%)
Time since stroke: 1 to 6 months prior to randomisation (average time 3 months)
Inclusion criteria: 1) unable to walk
Exclusion criteria: 1) history of major affective disorders; 2) alcohol abuse; 3) a history or evidence or
both of severe heart, lung, kidney or liver diseases or mental deterioration
Total number randomised in this study: 26
Number randomised to treatment group: 18 (44% men, mean age 68 years, SD 9)
Dam 1996a 
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Number randomised to control group: 8* (44% men, mean age 68 years, SD 6)
Total number included in final analysis: 24
Number included in treatment group for final analysis: 16
Number included in control group for final analysis: 8*
Interventions Treatment: fluoxetine (SSRI), 20 mg daily
Control: matched placebo




• Depression measured using the HDRS
Secondary outcomes
• Impairment measured using the Hemispheric Stroke Scale (HSS)
• Disability measured using the BI





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly divided into three groups and treated for 3
months with physical therapy associated with ..." pp. 2
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comments: blinding of participants and personnel was not reported
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "The examining neurologists were blinded to the treatment adminis-




High risk Comments: per protocol analyses reported only. 3/35 participants were not
included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-
ment and control group in baseline demographic characteristics
Dam 1996a  (Continued)
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Methods Study design: parallel design
Number of arms: 2
Experimental arm: maprotiline (tetracyclic agent)
Control arm: matched placebo
Participants Geographical location: Italy
Setting: unclear
Stroke criteria: ischaemic, unilateral MCA territory stroke.
Method of stroke diagnosis: via clinical signs and CT (100%)
Time since stroke: 1 to 6 months prior to randomisation (average time 3 months)
Inclusion criteria: 1) unable to walk
Exclusion criteria: 1) history of major affective disorders; 2) alcohol abuse; 3) a history or evidence or
both of severe heart, lung, kidney or liver diseases or mental deterioration
Total number randomised in this study: 26
Number randomised to treatment group: 17 (43% men, mean age 68 years, SD 8)
Number randomised to control group: 9* (44% men, mean age 68 years, SD 6)
Total number included in final analysis: 22
Number included in treatment group for final analysis: 14
Number included in control group for final analysis: 8*
Interventions Treatment: maprotiline (tetracyclic agent), 150 mg daily
Control: matched placebo




• Depression measured using the HDRS
Secondary outcomes
• Impairment measured using the Hemispheric Stroke Scale (HSS)
• Disability measured using the BI





Bias Authors' judgement Support for judgement
Dam 1996b 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly divided into three groups and treated for 3
months with physical therapy associated with ..." pp. 2
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comments: blinding of participants and personnel was not reported
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "The examining neurologists were blinded to the treatment adminis-




High risk Comments: per protocol analyses reported only. 3/35 participants were not
included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Treatment arm: specialist nurse intervention
Control arm: usual care
Participants Geographical location: UK
Setting: outpatient
Stroke criteria: all subtypes excluding cerebral haemorrhage
Method of diagnosis: via clinical signs and CT (% not reported)
Time since stroke: not reported
Inclusion criteria: 1) over 60 years; 2) disability related to stroke
Exclusion criteria: 1) multi-infarction dementia; 2) concurrent medical condition associated with a poor
prognosis; 3) lived in residential care
Total number randomised in this study: 240
Number randomised to treatment group: 120 (55% men, median age 73 years, range 60 to 94 years)
Number randomised to control group: 120 (51% men, median age 73 years, range 60 to 90 years)
Total number included in final analysis: 208
Forster 1996 
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Number included in treatment group for final analysis: 103
Number included in control group for final analysis: 105
Interventions Treatment: specialist nurse intervention; included a counselling and enabling model, specialised in
problem solving, goal setting, advice on specific issues plus information booklets
Treatment duration: treatment continued for a minimum 6 visits over the first 6 months (average of 8
visits over first 6 months)
Administed by: specialist G-grade nurses experienced in assessing disability in elderly and in problem
solving approaches
Supervision: not reported
Intervention fidelity: not reported
Control: usual care, no visits
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the Nottingham Health Profile (NHP)
Secondary outcomes
• Physical function measured using the NHP,
• Disability measured using the BI




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "An assistant in our department who was otherwise unconnected with
the study randomized the patients by 4 length random permuted blocks of 6 to
the control group or the intervention group (the patients receiving visits by the
specialist nurses)." pp. 1642
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comments: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Comments: per protocol analysis reported only. 33/240 participants not in-
cluded in the analysis
Forster 1996  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number arms: 2
Treatment arm: home-based therapeutic intervention
Control arm: usual care
Participants Geographical location: USA
Setting: inpatient
Stroke criteria: unclear.
Method of stroke diagnosis: unclear.
Time since stroke: on average 2 weeks (treatment group) and 13 weeks (control group) prior to ran-
domisation
Inclusion criteria: 1) home to return to and readily identified primary caregiver
Exclusion criteria: 1) severe pre-morbid or co-morbid conditions sufficient to impact significantly on
their capacity to recover from the stroke; 2) residual cognitive or communicative impairment prevent
participation in interviews
Total number randomised in this study: 55
Number randomised to treatment group: 27 (48% men, median age 72 years, range 65 to 84 years)
Number randomised to control group: 28 (55% men, median age 72 years, range 65 to 81 years)
Total number included in final analysis: 41
Number included in treatment group for final analysis: 21
Number included in control group for final analysis: 20
Interventions Treatment: weekly phone contact, monthly home visits; home-based therapeutic team attend specifi-
cally to psychosocial stressors and prevent significant psychosocial problems from accelerating
Treatment duration: treatment continued for 1 year
Administered by: multidisciplinary team included a psychiatrist, psychologist, recreational therapist,
research programme case manager, social worker
Supervision: case manager (social worker)
Intervention fidelity: not reported
Control: usual care, no visits
Follow-up: last follow-up at 1 year (end of treatment)
Goldberg 1997 
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Outcomes Primary outcomes
• Depression measured using the CES-D
Secondary outcomes




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "... subjects were randomized using a random number table to either
the experimental group, which received the STAIR program, or to a control
group, which did not." pp. 67
Allocation concealment
(selection bias)





High risk Quote: "... since the subjects clearly could not be blinded to their own treat-
ment." pp. 67
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quote: "Blinding of the data collector was attempted, although this was diffi-
cult to consistently accomplish and maintain, since the subjects clearly could




High risk Comments: per protocol analysis reported only. 14/55 participants were not
included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: methylphenidate
Control arm: matched placebo
Participants Geographical location: USA
Setting: inpatient
Stroke criteria: all subtypes
Grade 1998 
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Method of stroke diagnosis: via clinical signs and CT (100%)
Time since stroke: on average 18 days (SE 4, treatment group) and 19 days (SE 4, control group) prior to
randomisation
Inclusion criteria: not reported
Exclusion criteria: 1) childbearing potential; 2) hypersensitivity to methylphenidate; 3) significant med-
ical conditions, schizophrenia, delusional disorder, motor tics, uncontrolled epilepsy, malignant hyper-
tension, prominent agitation; 4) current antidepressant treatment
Total number randomised in this study: 21
Number randomised to treatment group: 10 (40% men, mean age 70 years, SE 4)
Number randomised to control group: 11 (64% men, mean age 73 years, SE 3)
Total number included in final analysis: 21
Number included in treatment group for final analysis: 10
Number included in control group for final analysis: 11
Interventions Treatment: methylphenidate, 5 mg (1 in morning) to 60 mg (3 x 10 mg twice daily) daily; dose increased
if no adverse events reported
Control: matched placebo
Treatment duration: treatment continued for 3 to 4 weeks
Follow-up: not reported.
Outcomes Primary outcomes
• Depression measured using the HDRS and ZDS
Secondary outcomes
• Dependence measured using the FIM
• Cognitive function measured using the MMSE
• Leaving the study early
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Using a random numbers table, the pharmacy department randomly




Low risk Quote: "... assigned all patients to receive either methylphenidate or placebo





Low risk Quote: "All patients and their families, as well as nurses and clinical examin-
ers, were unaware of which participants were receiving methylphenidate." pp.
1048
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "To check the integrity of the double-blind design, a short question-
naire was given after the last rating period. Patients, examiners (psychiatrist,
physical therapist, and psychologist), and other study staE (nurses and physi-
atrist) were asked to indicate whether they believed the patient was given
Grade 1998  (Continued)
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Low risk Comments: ITT analysis reported
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: cognitive behavioural coping skills therapy
Control arm: usual care
Participants Geographical location: Australia
Setting: inpatient
Stroke criteria: unclear.
Method of stroke diagnosis: confirmed by chart review
Time since stroke: not reported
Inclusion criteria: 1) > 18 years old; 2) adequate cognitive capacity to provide informed consent; 3) ade-
quate English and expressive and receptive communication skills
Exclusion criteria: 1) neurodegenerative disorder e.g. dementia; 2) living > 50 km away from hospital
Depression criteria: depression score not an entry criteria. For unpublished analysis
HADS ≥ 8 used for depression criteria
Total number randomised in this trial: 16
Number randomised to treatment group: 11 (63.6% men, mean age 63.6, SD 13.0)
Number randomised to control group: 5 (60% men, mean age 57.0, SD 14.2)
Total number included in final analysis: 14
Number included in treatment group for final analysis: 9
Number included in control group for final analysis: 5
Interventions Treatment: 8 x 1-hour cognitive-behavioural coping skills sessions delivered by a clinical psychologist
with the first 2 in hospital and 6 delivered at home. The sessions included cognitive and behavioural ex-
ercises to prepare individuals for discharge and to adjust post-discharge (e.g. psychoeducation, self-
monitoring, graduated activity participation, and cognitive restructuring)
Treatment duration: 8 weeks
Administered by: clinical psychologist
Supervision: clinical psychologist
Intervention fidelity: 10/11 (90%) in the treatment group (1 discontinued after 1 session) completed the
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• Depression measured using the MADRS and the HADS
• Anxiety measured using the MADRS and the HADS
Secondary outcomes
• Activities of daily living measured using the MBI
• Stress coping measured using the Stress Appraisal Coping Measure
Notes This trial had 3 arms (self-management therapy, cognitive behavioural therapy and usual care) but only
the data from the cognitive behavioural therapy compared with usual care (n = 14 participants) are pre-
sented here
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "... randomly allocated using a predetermined computer generated
randomization sequence ..." pp. 118
Allocation concealment
(selection bias)





High risk Comments: due to the nature of the intervention blinding will not be achiev-
able for participants or staE delivering care
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Outcomes were assessed in a face-to-face interview conducted by a





Low risk Quote: "Analysis was completed using ... and on an intention to treat basis and




Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 3
Experimental arm: problem-solving therapy
Control arm 1: non-specific volunteer visits
Control arm 2: usual care
Participants Geographical location: UK
Setting: outpatient
Stroke criteria: ischaemic stroke and primary intracerebral haemorrhage
House 2000 
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Method of stroke diagnosis: via clinical signs and CT (% not reported)
Time since stroke: 0 to 1 month prior to randomisation
Inclusion criteria: 1) local resident
Exclusion criteria: too ill to interview, impaired speech, cognitive impairment or poor English, living in a
residential home at admission, serious concurrent illness likely to dominate pattern of care, participa-
tion in another rehabilitation trial
Total number randomised in this study: 450
Number randomised to treatment group: 151 (56% men, median age 74 years, IQR 65 to 79)
Number randomised to control group 1: 149^ (49% men, median age 72 years, IQR 64 to 78)
Number randomised to control group 2: 150^ (57% men, median age 74 years, IQR 66 to 80)
Total number included in final analysis: 450
Number included in treatment group for final analysis: 151
Number included in control group 1 for final analysis: 149
Number included in control group 2 for final analysis: 150
Interventions Treatment: problem-solving therapy (manual-based): sessions in participants' home, help to identify
and prioritise problems, set goals and identify solutions to problems
Treatment duration: treatment continued for 1 to 10 (median 5) fortnightly sessions for treatment
group, 1 to 42 (median 6) fortnightly contacts for attention control group
Administered by: problem-solving therapy delivered by psychiatric nurses, attention control adminis-
tered by trained volunteers
Supervision: specialised liaison psychiatrist
Intervention fidelity: n = 121 participants received standard problem solving intervention, n = 30 did
not receive full intervention
Control: 1) attention control -non-specific volunteer visits, 2) Usual care, no visits
Follow-up: not reported
Outcomes Primary outcomes
• Depression (difference between groups at end of treatment) measured using the GHQ-28 total score**
• Depression (proportion scoring > 4) measured using the Present State Examination (PSE)
Secondary outcomes




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Random allocation was generated by computer in the trials office in
blocks of 15, stratified by admitting NHS trusts." pp. 2
House 2000  (Continued)
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Allocation concealment
(selection bias)
Low risk Quote: "Patients were sent a letter confirming their participation and giv-
ing the name of their volunteer or nurse, as appropriate, and the planned fol-
low-up dates. In this way, patients were not aware that their treatment was be-
ing randomly allocated, and did not know that other patients were receiving a





High risk Quote: "Patients were not masked to their allocation as this is clearly impos-
sible to achieve with this type of intervention. However, as a result of the ran-
domization procedure patients were unaware of other treatment allocations."
pp. 2
Comments: blinding of personnel not reported.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quote: "Follow up assessments took place in the patient’s home with an in-
terviewer who was not informed of the treatment allocation of the patient.
Patients who received problem-solving were asked by the therapist not to re-
veal their allocation. To test the extent of unmasking of outcome assessors,
we asked the interviewer to guess the allocation of 127 patients seen at 12
months." pp. 3
"The interviewer guessed correctly in 65 (51.2%) patients (kappa = 0.26, p <








Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: individual motivational interviewing
Control arm: usual care
Participants Geographical location: Australia
Setting: inpatient
Stroke criteria: acute presentation after acute stroke (cerebral infarction/intracerebral haemorrhage)
Method of stroke diagnosis: confirmed by neurologist in the medical notes
Time since stroke: not reported
Inclusion criteria: 1) acute presentation after acute stroke (cerebral infarction/intracerebral haemor-
rhage; 2) cognitively alert
Exclusion criteria: 1) mental health conditions, including depressive symptoms requiring profession-
al support within 1 month; 2) severe communication problems e.g. significant dysphasia or aphasia; 3)
myocardial infarction; 4) concurrent neurological disease/trauma; 5) subarachnoid haemorrhage
Depression criteria: depression score not an entry criteria.
Total number randomised in this trial: 28
Number randomised to treatment group: 14 (85.7% men, mean age 69.14, SD 10.91)
Number randomised to control group: 14 (50% men, mean age 71.95, SD 13.14)
Kerr 2018 
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression aer stroke (Review)









Cochrane Database of Systematic Reviews
Total number included in final analysis: 25
Number included in treatment group for final analysis: 12
Number included in control group for final analysis: 13
Interventions Treatment: 3 x 30-minute sessions of motivational interviewing. The purpose of Session 1 was to set the
agenda and encourage the patient to talk about adjustment to stroke. In Session 2, the patient was en-
couraged to identify realistic goals for recovery and identify barriers to achieving goals. In Session 3,
the goal was to identify any ambivalence the patient had about achieving goals; support the patient's
optimism and self-efficacy, and assist identification of solutions to solve problems. Participants were
encouraged to summarise their goals and commitment and clarify any information from the first 2 ses-
sions
Treatment duration: 3 months
Administered by: trained facilitators





• Depression measured using the HADS and the PHQ-9
• Anxiety measured using the HADS
Secondary outcomes
• Quality of life measured using the QoL Index
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "A computer-generated block randomization list equally divided all
numbers between 1 and 60 into either treatment or control groups." pp. 3
Allocation concealment
(selection bias)
High risk Quote: "Allocation to the intervention or control arms was concealed from
participants until after recruitment and baseline data collection. Envelopes
were prepared by the Principal Investigator and stored in a locked cupboard
in the ward. The envelopes were numbered sequentially, indicating the order
in which participants were enrolled into the study (e.g. the first participant re-
ceived the envelope labelled 'Number 1', the second participant received the
envelope 'Number 2', etc.). A note in the envelope indicated the allocation (to
intervention or control group), concealed by coloured paper to protect the
identity of the allocation group. The project manager opened the randomiza-





High risk Quote: "Allocation to the intervention or control arms was concealed from
participants until after recruitment and baseline data collection." pp. 3
Comments: blinding of personnel not reported
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quote: "The research assistant, a nurse with significant research experience,
was employed to collect data at the 2 follow-up time points. Although inten-
Kerr 2018  (Continued)
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tionally blinded, the research assistant may have become aware of the alloca-




High risk Comments: per protocol analysis reported in Table 1 and 2. 10/48 participants
were not included in the analysis. (8 dropped out; 2 unable to participate; 1
died, 1 developed aphasia)
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Quote: "Patients were broadly similar for age, gender, nationality, and marital
status. Capacity to perform activities of daily living were similar, according to
the Modified Barthel Index.” pp. 6





Methods Study design: parallel design
Number of arms: 2
Experimental arm: mianserin (tetracyclic agent)
Control arm: matched placebo
Participants Geographical location: Finland
Setting: unclear
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: via clinical signs and CT or MRI (100%)
Time since stroke: 0 to 30 days prior to randomisation (average 14.3 days)
Inclusion criteria: 1) under 71 years of age
Exclusion criteria: 1) other diseases severe enough to confound the assessments of stroke outcome (se-
vere cardiovascular, renal or liver disease, psychosis, alcoholism or dementia); 2) currently on antide-
pressants
Total number randomised in this study: 100
Number randomised to treatment group: 51 (71% men, mean age 56 years, SD 11)
Number randomised to control group: 49 (65% men, mean age 55 years, SD 10)
Total number included in final analysis: 64
Number included in treatment group for final analysis: 27
Number included in control group for final analysis: 37
Interventions Treatment: mianserin (tetracyclic agent),10 mg every night; within 10 days dosage increased to 60 mg
daily
Control: matched placebo
Treatment duration: treatment continued for 12 months
Palomaki 1999 
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Follow-up: 18 months
Outcomes Primary outcomes
• Depression (proportion not meeting criteria for major depression) measured using the DSM-III-R





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomized to mianserin or placebo groups of
equal size, stratified according to location of lesion ..." pp. 490
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)
High risk Quote: "The randomization codes were kept in sealed envelopes." pp. 491





Low risk Quote: "For each stratum, the test drugs were provided in numbered vials con-
taining tablets of identical appearance." pp. 491
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Comments: per protocol analysis reported only. Only 75% of participants re-
mained in placebo and 52% remained in treatment group at 12 months and
were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: sertraline (SSRI)
Control arm: matched placebo
Participants Geographical location: Denmark
Setting: unclear
Rasmussen 2003 
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Stroke criteria: ischaemic and primary intracerebral haemorrhage
Method of stroke diagnosis: via clinical signs and symptoms
Time since stroke: 0 to 4 weeks prior to randomisation
Inclusion criteria: not reported
Exclusion criteria: 1) current depression; 2) significant aphasia or dementia; 3) history of schizophrenia;
4) psychosis or severe drug abuse; 5) pre-existing neurological illness; 6) antidepressants in preceding 4
weeks; 7) current (within 6 months) cardiovascular illness
Total number randomised in this study: 137
Number randomised to treatment group: 70 (50% men, mean age 72 years, SD 9)
Number randomised to control group: 67 (51% men, mean age 68 years, SD 11)
Total number included in final analysis: 118
Number included in treatment group for final analysis: 61
Number included in control group for final analysis: 57
Interventions Treatment: sertraline (SSRI), 50 mg daily; at any time after 2 weeks dose could be increased in 50 mg in-
crements up to 150 mg daily; average dose 62.9 mg daily
Control: matched placebo
Treatment duration: treatment continued for 12 months
Follow-up: not reported
Outcomes Primary outcomes
• Depression (change in scores from baseline to end of treatment) measured using the HDRS
• Depression (proportion scoring > 2) measured using the CGI
• Depression (proportion scoring > 16) measured using the GDS
Secondary outcomes
• Leaving the study early
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly assigned to 12 months of double-blind study
treatment." pp. 217
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Low risk Quote: title - "A double-blind, placebo-controlled study of sertraline in the pre-
vention of depression in stroke patients." pp. 216
Comments: who was blinded was not reported
Blinding of outcome as-
sessment (detection bias)
Low risk Quote: title - "A double-blind, placebo-controlled study of sertraline in the pre-
vention of depression in stroke patients." pp. 216
Rasmussen 2003  (Continued)
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Unclear risk Comments: no trial protocol available to compare with the publication





Methods Study design: parallel design
Number of arms: 2
Experimental arm: trazodone-HCl (serotonin modulator)
Control arm: matched placebo
Participants Geographical location: USA
Setting: inpatient
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical signs and CT (100%)
Time since stroke: on average 45 +/- 5 days (treatment group) and 48 +/- 13 days (control group) prior to
randomisation
Inclusion criteria: not reported
Exclusion criteria: 1) myocardial infarction within previous month; 2) antiarrhythmic medication
Total number randomised in this study: 27
Number randomised to treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: 5
Number included in treatment group for final analysis: 3 (66% men, mean age 67 years, SE 6)
Number included in control group for final analysis: 2 (50% men, mean age 73 years, SE 16)
Interventions Treatment: trazodone-HCl (serotonin modulator) 50 mg daily; dose escalation every 3 days to target
dose of 200 mg
Control: matched placebo




• Depression measured via clinical diagnosis of depression
Reding 1986 
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Secondary outcomes
• Activities of daily living measured using the BI
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were assigned to either treatment or placebo groups accord-
ing to a table of random numbers." pp. 763
Allocation concealment
(selection bias)





Low risk Quote: "Trazodone hydrochloride (50 mg) or placebo in an identical capsule
was administered orally by the nursing staE ..." pp. 763
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "... attending physician, unaware of treatment group assignment, not-




High risk Comments: only 5/27 patients completed the study at target dose. The study
was discontinued due to perceived side effects in both groups. The analysis




Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: USA and Argentina
Setting: mixed
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical signs and CT (100%)
Time since stroke: on average 8 weeks (treatment) and 5 weeks (control) prior to randomisation
Inclusion criteria: 1) stroke within 6 months of recruitment; 2) 18 to 85 years of age
Robinson 2000a 
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Exclusion criteria: 1) other significant medical illness; 2) severe comprehension deficit; 3) prior histo-
ry of head injury; 4) prior history of other brain disease (with the exception of stroke); 5) participants
on antidepressants (other than fluoxetine) were allowed to stop their antidepressants for a 2-week
washout period
Total number randomised in this study: 25
Number randomised to treatment group: 17 (88% men, mean age 66 years, SD 13)
Number randomised to control group: 8* (75% men, mean age 67 years, SD 9)
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: fluoxetine (SSRI),10 mg daily (3 weeks), 20 mg daily (3 weeks), 30 mg daily (3 weeks), 40 mg
daily (3 weeks)
Control: matched placebo
Treatment duration: treatment continued for 12 weeks
Follow-up: none
Outcomes Primary outcomes
• Depression measured using the HDRS
Secondary outcomes
• Cognitive function measured using the MMSE





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "All patients were randomly assigned to either active or placebo med-
ication." pp. 352
Comments: method of sequence generation not reported.
Allocation concealment
(selection bias)





Low risk Quote: "To maintain the blind, doses were decreased for equal numbers of
placebo patients. The active and placebo pills were identical." pp. 353
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Comments: blinding of outcome assessment not reported. However, the




High risk Comments: Table 1 presents ITT analysis but per protocol analyses reported.
The number excluded from analysis varies
Robinson 2000a  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: nortriptyline (tricyclic agent)
Control arm: matched placebo
Participants Geographical location: USA and Argentina
Setting: mixed
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical signs and CT (100%);
Time since stroke: on average 10 weeks (treatment) and 5 weeks (control) prior to randomisation
Inclusion criteria: 1) stroke within 6 months of recruitment; 2) 18 to 85 years of age
Exclusion criteria: 1) other significant medical illness; 2) severe comprehension deficit; 3) prior histo-
ry of head injury; 4) prior history of other brain disease (with the exception of stroke); 5) participants
on antidepressants (other than fluoxetine) were allowed to stop their antidepressants for a 2-week
washout period
Total number randomised in this study: 23
Number randomised to treatment group: 15 (47% men, mean age 65 years, SD 13)
Number randomised to control group: 8* (75% men, mean age 67 years, SD 9)
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: nortriptyline (tricyclic agent), 25 mg daily (1 week), 50 mg daily (2 weeks), 75 mg daily (4
weeks), 100 mg daily (6 weeks)
Control: matched placebo
Treatment duration: treatment continued for 12 weeks
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the HDRS
Secondary outcomes
• Cognitive function measured using the MMSE
• Activities of daily living measured using the Johns Hopkins Functioning Inventory
Robinson 2000b 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "All patients were randomly assigned to either active or placebo med-
ication." pp. 352
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Low risk Quote: "To maintain the blind, doses were decreased for equal numbers of
placebo patients. The active and placebo pills were identical." pp. 353
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Comments: blinding of outcome assessment not reported. However, the




High risk Comments: Table 1 presents ITT analysis but per protocol analyses reported.
The number excluded from analysis varies
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: escitalopram (SSRI)
Control arm: matched placebo
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: ischaemic or cerebellar stroke
Method of stroke diagnosis: based on clinical and neuro-radiological findings consistent with either
hemispheric, brainstem or cerebellar stroke
Time since stroke: not reported
Inclusion criteria: 1) patients with either ischaemic or cerebellar stroke
Exclusion criteria: 1) if they met DSM-IV diagnostic criteria for major or minor (research criteria) depres-
sive disorder; 2) those with severe comprehension deficit as demonstrated by inability to complete part
1 of the Token Test or patients with neuropsychological testing who showed impaired decision-mak-
Robinson 2008 
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ing capacity; 3) patients with acute coronary syndromes; 4) those with stroke as secondary complica-
tions from an intracranial aneurysm, arterial-venous malformation, stroke from a myocardial infarc-
tion, aortic dissection or revascularization therapy; 5) life-threatening heart or respiratory failure, re-
nal or hepatic failure, severely disabling musculoskeletal disorder, cancer and neurodegenerative dis-
orders such as idiopathic Parkinson disease or Alzheimer disease; 6) those who met the DSM-IV criteria
for alcohol or substance abuse or dependence within the past 12 months
Depression criteria: depression score not an entry criteria
Total number randomised in this trial: 117
Number randomised to treatment group: 59 (64.4% men, mean age 61.3, SD 13.7)
Number randomised to control group: 58 (63.8% men, mean age 63.9, SD 13.3)
Total number included in final analysis: 117
Number included in treatment group for final analysis: 59
Number included in control group for final analysis: 58
Interventions Treatment: escitalopram (SSRI) 10 mg/day (morning) for participants < 65 years and 5 mg/day for par-
ticipants > 65 years
Control: matched placebo
Treatment duration: 12 months
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the 17-item HDRS
Secondary outcomes
• Activities of daily living measured using the ADL Index
• Social function measured using the Social Functioning Examination
Notes This trial had 3 arms (escitalopram, problem-solving therapy and placebo) but only the data from the
escitalopram group compared with placebo (n = 117 participants) are presented here
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "... each block patients were randomly assigned 1 of the 3 treatments









Low risk Quote: "all pills were identical ..." pp. 2393
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Patients were seen for evaluation by raters who were blinded to drug




Low risk Comments: ITT analysis was reported. All participants were included in the
analysis despite dropouts
Robinson 2008  (Continued)
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Selective reporting (re-
porting bias)
High risk Comments: did not report the results for anxiety
Other bias Low risk Quote: "There were no significant differences between the groups in age, sex,
years of education, marital status, or socioeconomic status."
"There were no significant inter-group differences in overall cumulative illness
scores, coronary artery disease, low-density lipoprotein cholesterol, atrial fib-
rillation, chronic obstructive pulmonary disease, or systolic blood pressure.
The patients randomized to escitalopram, however, had a significantly greater






Methods Study design: parallel design
Number of arms: 2
Experimental arm: indeloxazine (tricyclic agent)
Control arm: matched placebo
Participants Geographical location: Korea
Setting: unclear
Stroke criteria: ischaemic stroke
Method of stroke diagnosis: via clinical signs and symptoms and CT (100%)
Time since stroke: unclear
Inclusion criteria: 1) mental and neurological symptoms for 1 to 3 months attributed to cerebral infarc-
tion
Exclusion criteria: 1) Alzheimers disease; 2) unstable patients (stroke occurring within 1 month); 3) dis-
turbance of consciousness; 4) severe dementia (MMSE < 20); 5) unable to communicate adequately
with investigator; 6) advanced hepatic, renal or cardiac circulatory impairment; 7) pregnancy, possibili-
ty of becoming pregnant; 8) under 20 years of age; 9) those judged unsuitable for participation by inves-
tigators
Total number randomised in this study: 65
Number randomised to treatment group: 32 (90% men, mean age unclear)
Number randomised to control group: 33 (87% men, mean age unclear)
Total number included in final analysis: 60
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 30
Interventions Treatment: indeloxazine (tricyclic agent), 20 mg daily
Control: matched placebo
Treatment duration: continued for 3 months
Follow-up: not reported
Roh 1996 
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Outcomes Primary outcome
• Depression measured using the physician assessment of change in emotional disturbance from base-
line to end of treatment
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were assigned by using a table of random numbers to receive




Low risk Quote: "The placebo and test drug were given in identical tablet form to en-





Low risk Quote: "The placebo and test drug were given in identical tablet form to en-
sure double-masking." pp. 633-4
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "The placebo and test drug were given in identical tablet form to en-




High risk Quote: "Of the 33 patients in the placebo group, 2 patients complained of
headache and 1 showed a deterioration in eyesight: these patients withdrew
from the study and were not included in the analysis." pp. 636-7
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: milnacipran (SNRI)
Control arm: matching placebo
Participants Geographical location: Taiwan
Setting: inpatient
Stroke criteria: first ischaemic or recurrent stroke
Method of stroke diagnosis: confirmed by imaging
Time since stroke: 4 weeks before admission
Inclusion criteria: 1) first or recurrent ischaemic stroke
Exclusion criteria: 1) with past history of depression, substance abuse or psychosis; 2) taking antide-
pressants at least two weeks before stroke; 3) MMSE <15; 4) impairment of communication; 5) TIA; 6)
had possible concurrent depression (HDRS > 10).
Tsai 2011 
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Depression criteria: HDRS > 10
Total number randomised in this trial: 92
Number randomised to treatment group: 46 (65.2% men, mean age 61.0, SD 10.8)
Number randomised to control group: 46 (63% men, mean age 64.9, SD 10.5)
Total number included in final analysis: 56
Number included in treatment group for final analysis: 25
Number included in control group for final analysis: 31
Interventions Treatment: milnacipran (SNRI), 50 mg/day titrated to 100 mg/day
Control: matching placebo
Treatment duration: 12 months
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the HDRS
Secondary outcomes
• Quality of life measured using the QoL Index
• Disability measured using the London Handicap Scale
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The randomization was carried out by our pharmacy department,
which has a professional team in charge of the clinical drug trials in our hospi-
tal." pp. 264
Comments: method of sequence generation not reported
Allocation concealment
(selection bias)
Low risk Quote: "They prepared the drug with an allocation number for each partici-





Low risk Quote: "The placebo was tailor-made, and the appearance and weight (starch
inside) were the same as that of the active drug, milnacipran." pp. 265
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: "Fi(y-six (60.9%) of 92 patients completed 12 months of study treat-
ment: 25 (54.3%) of 46 in the treatment group and 31 (67.4%) of 46 in the
placebo group, respectively." pp. 265
Comments: Figure 1 and Table 1 presents ITT analysis. All 92 participants were
included in the analysis
Selective reporting (re-
porting bias)
Low risk Quote: "The modified version of the 17-item HDRS without item 14 (sexual be-
havior), NIHSS, and BI, were assessed in each of the follow-up visits. The defin-
ition of PSD in the study was based on the diagnostic criteria of major depres-
sive episode in DSM-IV by professional psychiatrists."
Tsai 2011  (Continued)
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Other bias Unclear risk Comments: treatment group appears to contain higher proportion of partici-






Methods Study design: parallel design
Number of arms: 2
Experimental arm: motivational interviewing
Control arm: usual care
Participants Geographical location: UK
Setting: inpatient
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical signs and CT (97%)
Time since stroke: 5 to 28 days prior to randomisation
Inclusion criteria: 1) over 18 years
Exclusion criteria: 1) severe cognitive and communication problems; 2) moving out of the area after dis-
charge; 3) already receiving psychiatric or clinical psychology intervention
Total number randomised in this study: 157
Number randomised to treatment group: 77 (69% men, mean age 70 years, SD 10)
Number randomised to control group: 80 (70% men, mean age 70 years, SD 10)
Total number included in final analysis: 157
Number included in treatment group for final analysis: 77
Number included in control group for final analysis: 80
Interventions Treatment: motivational interviewing
Treatment duration: treatment was up to 4 sessions, 1 per week, with same therapist
Administered by: nursing and psychology (non-clinical) staE,
Supervision: by a clinical psychologist
Intervention fidelity: 16/204 did not receive any intervention sessions. 188/204 received at least one




• Depression measured using the GHQ-28
Secondary outcomes
Watkins 2007 
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• Depression measured using the Yale Depression Screen
• Activities of daily living measured using the BI
Notes Additional unpublished data provided by authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "A research nurse randomized patients (1:1 ratio) to either usual care
(control) or MI (intervention) using minimization over sex, age (65 and 65
years), baseline function in activities of daily living (ADL; Barthel: 18 to 20; 11 to
17; 0 to 10),24 and location (acute stroke unit or not)." pp. 1957
Comments: method of sequence generation not reported.
Allocation concealment
(selection bias)
High risk Quote: "The same nurse then assigned intervention group patients to 1 of 4






High risk Quote: "The therapists were not involved in the initial assessment of patients,
randomization, or assignment of patients to therapists." pp. 1957
Comments: the same research nurse randomised and assigned patients to
therapists
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quote: "Surviving patients were sent a questionnaire. Patients not returning
questionnaires within 2 weeks were telephoned by a second research nurse,
blind to group allocation, and given the option of declining, having a further
questionnaire posted, completing the questionnaire over the telephone, or re-




Low risk Comments: Figure 1 shows the trial profile. Under analysis, it states that all
participants were included in the analysis. Missing data were imputed
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: there was no statistically significant difference between the treat-





Methods Study design: parallel design
Number of arms: 2
Experimental arm: solution focused brief therapy
Control arm: no psychotherapeutic interventions
Participants Geographical location: Poland
Setting: inpatient
Stroke criteria: first ischaemic stroke
Method of stroke diagnosis: confirmed by imaging
Wichowicz 2017 
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Time since stroke: 30 days
Inclusion criteria: 1) first ischaemic stroke
Exclusion criteria: 1) extensive intellectual defects precluding verbal contact, dementia (MMSE < 23
points); 2) aphasia; 3) severe dysarthria; 4) severe paresis; 5) NIHSS scale > 21; (6) aged > 65 years
Depression criteria: depression score not an entry criteria
Total number randomised in this trial: 100
Number randomised to treatment group: 51 (% men not reported, mean age 53.3, SD 9.9)
Number randomised to control group: 49 (% men not reported, mean age 54.2, SD 9.4)
Total number included in final analysis: 62
Number included in treatment group for final analysis: 30
Number included in control group for final analysis: 32
Interventions Treatment: solution focused brief therapy
Treatment duration: 84 days
Administered by: a therapist
Supervision: not reported
Intervention fidelity: 30/51 received allocated intervention, 21/51 did not receive allocated interven-
tion. 32/49 received control intervention, 17/49 did not receive control allocation
Control: no therapeutic interventions
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the HADS
• Anxiety measured using the HADS
Secondary outcomes
• Disability measured using the RS
• Activities of daily living measured using the BI
• Impairment measured using the NIHSS
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "They were assigned by simple random allocation to one of two
groups ..." pp. 1508
Comments: sequence generation was done through random number tables
(according to the study author)
Allocation concealment
(selection bias)
Unclear risk Quote: "Allocation sequence was concealed until participation was pro-
posed." pp. 1508





High risk Comments: participants were not blinded according to the author. Personnel
were not blinded according to the author
Wichowicz 2017  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "All assessments were conducted and interpreted by one researcher




Low risk Comments: ITT analysis reported. All participants allocated to the interven-
tion were included in the analysis
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Quote: "There were no significant differences in the age, education and the
physical function between the groups as shown in Table 1." pp. 1509





Methods Study design: parallel design
Number of arms: 2
Experimental arm: paroxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: China
Setting: inpatient
Stroke criteria: haemorrhagic cerebrovascular disease
Method of stroke diagnosis: met the criteria of the Fourth National Symposium on Cerebrovascular Dis-
ease in 1995 and confirmation by brain CT or MRI
Time since stroke: within 3 days
Inclusion criteria: 1) < 75 years old; 2) no cognitive impairment affecting communication; 3) no hepatic
or renal impairment; 4) stroke onset is within 3 days
Exclusion criteria: 1) history of psychiatry illness
Depression criteria: meeting the diagnostic criteria of DSM-IV
Total number randomised in this trial: 64
Number randomised to treatment group: 32 (53.1% men, mean age 65, SD 12)
Number randomised to control group: 32 (50% men, mean age 63, SD 11)
Total number included in final analysis: 57
Number included in treatment group for final analysis: 28
Number included in control group for final analysis: 29
Interventions Treatment: paroxetine (SSRI) 20 mg/day
Control: matched placebo
Treatment duration: 12 weeks
Follow-up: not reported
Outcomes Primary outcomes
• Depression measured using the DSM-IV
Secondary outcomes
• Disability measured using the MBI
Xu 2006 
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• Impairment measures using the Modified Edinburgh Stroke Scale (MESS)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comments: method of sequence generation not reported
Allocation concealment
(selection bias)





Unclear risk Comments: blinding of participants and personnel not reported
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Comments: ITT analysis reported but 7/64 dropped out, how missing data
were handled was not reported
Selective reporting (re-
porting bias)
Unclear risk Comments: no trial protocol available to compare with the publication
Other bias Low risk Comments: no differences in age, gender, Modified Edinburgh Stroke Scale or
ADL scales
Xu 2006  (Continued)
*: control group numbers and values halved to enable comparison with each active intervention
^: results for attention control and control group pooled
ADL: activities of daily living
BDI: Beck Depression Inventory
BI: Barthel Index
BOP: Beoordelingsschaal voor Oudere Patiënten (also known as Behavioural Rating Scale)
CES-D: Center for Epidemiologic Studies-Depression scale
CGI: Clinical Global Impression of Depression
CT: computed tomography
CVA: cerebrovascular accident
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition
FIM: Functional Independence Measure
GDS: Geriatric Depression Scale
GHQ-28: 28-item General Health Questionnaire
HADS: Hospital Anxiety and Depression Scale
HDRS: Hamilton Depression Rating Scale
HSS: Hemispheric Stroke Scale




MADRS: Montgomery–Åsberg Depression Rating Scale
MBI: Modified Barthel Index
MCA: middle cerebral artery
mRS: modified Rankin Scale
MMSE: Mini Mental State Examination
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MRI: magnetic resonance imaging
PHQ-9: 9-item Patient Health Questionaire




SNRI: serotonin and norepinephrine reuptake inhibitors
SSRI: selective serotonin reuptake inhibitors
TIA: transient ischaemic attack
ZDS: Zung Depression Scale
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aben 2014 Depression is not the primary outcome of the study
Agnoli 1985 Unable to isolate data for participants with stroke only
Bramanti 1989 Results not available in suitable format for the review
Casella 1960 Depression is not the primary outcome of the study
Choi-Kwon 2006 Unable to isolate outcome data for non- depressed participants at randomisation
Downes 1995 Unable to isolate outcome data for non- depressed participants at randomisation
F.X. 1976 Unable to isolate participants with stroke only
Friedland 1992 Results not available in suitable format for the review
Graffingo 2003 Results not available
Hadidi 2014 Unable to isolate outcome data for non- depressed participants at randomisation
Ijzerman 2005 Depression is not the primary outcome of this study
Isenberg 2000 Results not available
Kim 2017 Unable to isolate outcome data for non-depressed participants at randomisation
Kim 2017a Participants were depressed at baseline
Laska 2005 Depression is not the primary outcome of this study
Latow 1983 Results not available
Leathley 2003 Results not available in format suitable for this review
Leijon 1989 Depression is not the primary outcome of this study
Lobjanidze 2010 Depression is not the primary outcome of this study
Martucci 1986 Unable to isolate data for participants with stroke only
McCafferty 2000 Results not available
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Study Reason for exclusion
Ohtomo 1985 Results not available
Ostwald 2006 No usual care comparison
Ostwald 2014 Unable to isolate outcome data for non- depressed participants at randomisation
Otomo 1986 Unclear if depression is the primary outcome of the study
Poppitt 2009 Intervention did not meet review criteria
Raffaele 1996 Unable to isolate outcome data for non- depressed participants at randomisation
Sasaki 2017 Depression is not the primary outcome of this study
Sivenius 2001 Depression is not the primary outcome of this study
Walker-Batson 1995 Depression is not the primary outcome of this study
Yamamoto 1999 Unclear if depression is the primary outcome of the study
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Study design: parallel design
Number of arms: 2
Treatment arm: rational emotive behaviour therapy (REBT) + regular care
Control arm: prescribed medications (i.e. antithrombotic, vasodilators, neurotrophic drugs) and re-
habilitation training programs for physical functioning
Participants Geographical location: China
Setting: inpatient
Stroke criteria: patients with hemiplegic stroke
Method of stroke diagnosis: based on the diagnostic criteria set at the National Fourth Cerebrovas-
cular Disease Conference. Each patient’s condition was confirmed with a CT or MRI scan
Time since stroke: less than 2 weeks
Inclusion criteria: 1) patients with hemiplegic stroke, 2) patients who were less than 2 weeks post-
stroke
Exclusion criteria: 1) MMSE score of < 24, 2) severe aphasia, 3) those who failed to complete the
treatment, including those who died or stopped the treatment by choice, 4) history of psychiatric
illness
Depression criteria: Chinese version of the HDRS. Mean depression score used rather than depres-
sion cut oE
Total number randomised in this trial: 77
Number randomised in treatment group: 39
Chang 2011 
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Number randomised to control group: 38
Total number included in final analysis: 66
Number included in treatment group for final analysis: 34
Number included in control group for final analysis: 32
Interventions Treatment: REBT + regular care. Counselling, which consisted of a knowledge component: edu-
cation about health psychology and recovery from hemiplegic stroke; and a behavioural training
component including belief changes forgiveness training and anger management
Treatment duration: 1-2 hours weekly for 1 month
Administerd by: treatment group: by trained psychology graduate; regular care: administered by
the hospital nurses
Supervision: not reported
Intervention fidelity: those who failed to complete the intervention were excluded from the study.
34/39 completed in the treatment arm. 32/38 completed in the control arm
Control: prescribed medications (i.e. antithrombotic, vasodilators, neurotrophic drugs) and reha-
bilitation training programs for physical functioning
Follow-up: not reported
Outcomes Primary outcomes
• Anger management measured using the State Trait Anger Expression Inventory (STAXI)
• Anxiety measured using the Chinese version of the HDRS
• Depression measured using the Chinese version of the HDRS
Secondary outcomes
• Activities of daily living measured using the Chinese version of the BI





Methods Study design: parallel design
Number of arms: 2
Treatment arm: telephone counselling
Control arm: usual care
Participants Geographical location: USA
Setting: outpatient
Stroke criteria: unclear (also includes people with spinal cord injury, CNS disease and 'other')
Method of stroke diagnosis: not reported
Time since stroke: not reported
Evans 1985 
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Inclusion criteria: 1) clients discharged from rehabilitation centre; 2) housebound; 3) able to hear;
4) ordinary speech; and 5) sufficient cognitive ability to engage in meaningful conversation
Exclusion criteria: not reported
Depression criteria: score taken from the Life satisfaction Index (LSI), unclear how scored
Total number randomised in this trial: 38
Number randomised in treatment group: 19 (95% men, mean age 54.8 years, SD 11.9 years) - 4
stroke participants
Number randomised to control group: 19 (95% men, mean age 54.8 years, SD 10.2 years) - 5 stroke
participants
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: 8 weekly hour-long counselling sessions by phone with groups of 4 clients. Formulation
of behaviourally-specific goals was encouraged and developed with each client and discussion was
directed at finding ways to meet those goals
Administered by: an experienced counsellor
Supervision: not reported
Intervention fidelity: not reported
Control: usual care (no contact)
Treatment duration: not reported
Follow-up: not reported
Outcomes Primary outcome
• Depression using Life satisfaction Index (LSI)





Methods Study design: parallel design
Number of arms: 2
Treatment arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: Iran
Setting: unclear
Stroke criteria: cerebral ischaemic stroke
Method of stroke diagnosis: unclear
IRCT201112228490N1 
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Time since stroke: unclear
Inclusion criteria: 1) informed consent; 2) unilateral occlusion of MCA trunk; 3) resident in Rasht; 4)
admission NIHSS < 20; 5) no history of alcohol abuse; 6) no history of insomnia, epilepsy; 7) no pre-
vious history of cerebral haemorrhage and heart of cerebral stroke; 8) no previous history of sys-
temic diseases of other organs, including liver failure and kidney; 9) absence of cardiac pace maker,
severe neuropathy, systemic vascular disease or major affective disorders; 10) absence of concomi-
tant stroke in an area other than the stroke of the MCA
Exclusion criteria: 1) dissatisfaction of patient during the study; 2) occurrence of serious adverse
drug affects at any time during drug administration; 3) alcohol abuse during the study period; 4)
occurrence of post stroke depression concomitant use of the mono amine oxidase inhibitors or
serotonergic drugs such as tricyclic antidepressants and SSRI
Depression criteria: none
Total number randomised in this trial: unclear
Number randomised in treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: fluoxetine (SSRI) 15 mg for the first month and 20 mg for the next 2 months
Control: matched placebo 15 mg for the first month and 20 mg for the next 2 months
Treatment duration: 3 months
Follow-up: unclear
Outcomes Primary outcomes
• Disability measured using the mRS
• Activities of daily living measured using the BI
• Functional recovery measured using the NIHSS
• Depression measured using the BDI
Secondary outcomes





Methods Study design: unclear
Number of arms: unclear
Treatment arm: group psychotherapy/ behavioural therapy/ antidepressants - combination un-
clear
Control arm: unclear
Participants Geographical location: unclear
Katz 1998 
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Setting: unclear
Stroke criteria: unclear
Method of stroke diagnosis: unclear




Total number randomised in this trial: unclear
Number randomised in treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear








• Depression (unclear what measure was used)
Secondary outcomes
• Cognitive impairment (unclear what measure was used)
• Functional recovery (unclear what measure was used)




Methods Study design: parallel design
Number of arms: 2
Treatment arm: fluoxetine (SSRI)
Control arm: matched placebo
Participants Geographical location: Iran
Razazian 2016 
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Setting: inpatient
Stroke criteria: acute Ischemic stroke, in MCA region
Method of stroke diagnosis: confirmed by radiological imaging (CT)
Time since stroke: not reported
Inclusion criteria: 1) stroke in MCA region that leads to monoparesis, hemiparesis or hemiplegia, 2)
stable condition
Exclusion criteria: 1) death, 2) pregnancy, 3) poor compliance with drugs and physiotherapy, 4) po-
tential drug complications, 5) metabolic disease, 6) stroke in anterior cerebral artery or posterior
cerebral artery
Depression criteria: not reported.
Total number randomised in this trial: 172
Number randomised in treatment group: 86
Number randomised to control group: 86
Total number included in final analysis: 150
Number included in treatment group for final analysis: 75
Number included in control group for final analysis: 75
Interventions Treatment: fluoxetine (SSRI) 20 mg once per day orally
Control: matched placebo
Treatment duration: 90 days
Follow-up: not reported
Outcomes Primary outcome
• Depression measured using the HDRS
Secondary outcomes




BDI: Beck Depression Inventory
BI: Barthel Index
CNS: central nervous system
CT: computed tomography
HDRS: Hamilton Depression Rating Scale
MCA: middle cerebral artery
MMSE: Mini Mental State Examination
MRI: magnetic resonance imaging
mRS: Modified Rankin Scale
NIHSS: National Institute of Health Stroke Scale
SD: standard deviation
SSRI: Selective Serotonin Reuptake Inhibitors
USA: United States of America
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Characteristics of ongoing studies [ordered by study ID]
 
Study name Promoting psychosocial well-being following stroke: study protocol for a randomized, controlled
trial
Methods Study design: parallel design
Number of arms: 2
Treatment arm: dialogue-based intervention to promote psychosocial well-being
Control arm: usual care
Participants Geographical location: Norway
Setting: outpatient
Stroke criteria: unclear
Method of stroke diagnosis: unclear




Total number randomised in this trial: unclear
Number randomised in treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
Interventions Treatment: the intervention consists of 8 one-to-one and a half hour dialogue-based sessions be-
tween the stroke survivor and a specially trained health professional (RN or OT). Each meeting has
a guiding topical outline, which addresses significant issues described in the research literature
(e.g. bodily changes, emotional challenges, personal relations, daily life issues, meaningful activi-
ties, existential issues, important values, etc)
Administered by: a specially trained health professional (RN or OT)
Supervision: not reported
Intervention fidelity: not reported
Control: the control group receives treatment as usual and no intervention beyond participation
in the assessment interviews at 1, 6, and 12 months. As participants are recruited from a variety of
settings (acute stroke care and rehabilitation units), we anticipate some variation in the usual care
provided
Treatment duration: 8 sessions
Follow-up: 6- and 12-month assessments
Outcomes Primary outcome
Kirkevold 2018 
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• Depressive symptoms and anxiety (measured by GHQ-28)
Secondary outcomes
• Sense of coherence measured using the SOC-13
• Health-related quality of life measured using the SAQOL-39
Starting date December 2014
Contact information E: marit.kirkevold@medisin.uio.no;
Institute of Health and Society and Research Center for Rehabilitation and Rehabilitation services





Study name Prevention of poststroke depression after acute ischemic stroke using the selective serotonine re-
uptake inhibitor sertraline: "PreDIS-Study"
Methods Study design: parallel design
Number of arms: 2
Treatment arm: sertraline (SSRI)
Control arm: matched placebo
Participants Geographical location: Germany
Setting: mixed
Stroke criteria: unilateral ischaemic stroke
Method of stroke diagnosis: unclear
Time since stroke: 3 to 6 days prior to randomisation
Inclusion criteria: unclear
Exclusion criteria: 1) early and complete recovery from neurological symptoms; 2) mechanically
ventilated for more than 2 days; 3) severe aphasia or dementia; 4) already on antidepressant
Depression criteria: none
Total number randomised in this trial: unclear
Number randomised in treatment group: unclear
Number randomised to control group: unclear
Total number included in final analysis: unclear
Number included in treatment group for final analysis: unclear
Number included in control group for final analysis: unclear
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Treatment duration: treatment to continue for 6 months
Follow-up: unclear
Outcomes Primary outcomes
• Depression measured using the HADS, MADRS and ICD-10 diagnostic criteria
Secondary outcomes
• Activities of daily living measured using the BI
• Functional capacity measured using the mRS
• Cognitive function measured using the MMSE
• Impairment measured using the European Stroke Scale
• Quality of life measured using the SF-36
Starting date August 2001
Contact information Dr. Matthias Sitzer, Zentrum der Neurologie und Neurochirurgie JW Goethe-Universitat Frankfurt




GHQ-28: 28-item General Health Questionnaire
HADS: Hospital Anxiety and Depression Scale
ICD-10: International Classification of Disease- 10
MADRS: Montgomery Asberg Depression Rating Scale
MMSE: Mini Mental State Examination
mRS: modified Rankin Scale
OT: occupational therapist
RN: registered nurse
SAQOL-39: 39-item Stroke Aphasia Quality of Life Scale
SF-36: 36-item Short Form Questionnaire
SOC-13: 13-item Sense of Coherence Scale
SSRI: selective serotonin reuptake inhibitors
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Pharmacological interventions (antidepressants) versus placebo





Statistical method Effect size
1.1 Depression: meeting study criteria for
depression at end treatment
9 734 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.37, 0.68]
1.1.1 CGI (high score = more severe) 1 137 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.34, 1.15]
1.1.2 Clinician interview/impression (no
improvement)
1 65 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.26, 0.79]
1.1.3 Meets DSM-III-R criteria 3 148 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.27, 1.42]
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Statistical method Effect size
1.1.4 Meets DSM-IV criteria 2 181 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.15, 0.69]
1.1.5 HADS (high score = more severe) 1 111 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.32, 1.70]
1.1.6 HDRS (high score = more depressed) 1 92 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.02, 1.12]
1.2 Scoring above cut-oE points for a de-
pressive disorder at end of treatment
0   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
1.3 Depression: average change in scores
between baseline and end of treatment
5 211 Std. Mean Difference (IV, Random, 95%
CI)
-0.05 [-0.33, 0.23]
1.3.1 HDRS (high score = more depressed) 4 100 Std. Mean Difference (IV, Random, 95%
CI)
-0.16 [-0.58, 0.26]
1.3.2 HADS (high score = more depressed) 1 111 Std. Mean Difference (IV, Random, 95%
CI)
0.04 [-0.34, 0.41]
1.4 Depression: mean scores at end of
treatment
4 100 Mean Difference (IV, Random, 95% CI) 0.59 [-1.46, 2.63]
1.4.1 HDRS (high score = more depressed) 4 100 Mean Difference (IV, Random, 95% CI) 0.59 [-1.46, 2.63]
1.5 Cognition: average change in scores
between baseline and end of treatment
3 159 Mean Difference (IV, Random, 95% CI) 0.11 [-1.02, 1.24]
1.5.1 MMSE (low score = cognitive impair-
ment)
3 159 Mean Difference (IV, Random, 95% CI) 0.11 [-1.02, 1.24]
1.6 Cognition: Mean scores at end of
treatment
2 48 Mean Difference (IV, Random, 95% CI) -0.42 [-2.60, 1.76]
1.6.1 MMSE (low score = cognitive impair-
ment)
2 48 Mean Difference (IV, Random, 95% CI) -0.42 [-2.60, 1.76]
1.7 Activities of daily living: average
change in scores between baseline and
end of treatment
3 57 Mean Difference (IV, Random, 95% CI) 1.18 [-7.77, 10.14]
1.7.1 Barthel Index (high score = more de-
pendent)
3 57 Mean Difference (IV, Random, 95% CI) 1.18 [-7.77, 10.14]
1.8 Activities of daily living: mean scores
at end of treatment
3 116 Mean Difference (IV, Random, 95% CI) -3.86 [-9.48, 1.77]
1.8.1 Barthel Index (high score = more de-
pendent)
2 52 Mean Difference (IV, Random, 95% CI) 0.75 [-12.97, 14.47]
1.8.2 Activities of daily living Index (high
score = more dependent)
1 64 Mean Difference (IV, Random, 95% CI) -5.18 [-7.38, -2.98]
1.9 Disability: average change in scores
between baseline and end of treatment
4   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
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Statistical method Effect size
1.9.1 Hemispheric Stroke Scale Total
Score (high score = more neurological
deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.9.2 Hemispheric Stroke Scale Motor
Subscale (high score = more deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.9.3 Hemispheric Stroke Scale Gait Sub-
scale (high score = more deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.9.4 Johns Hopkins Functioning Invento-
ry (high score = less function)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.10 Disability: mean scores at end of
treatment
4   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.10.1 Hemispheric Stroke Scale total
score (high score = more neurological
deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.10.2 Hemispheric Stroke Scale motor
subscale (high score = more deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.10.3 Hemispheric Stroke Scale gait sub-
scale (high score = more deficit)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.10.4 Johns Hopkins Functioning Inven-
tory (high score = less function)
2   Mean Difference (IV, Random, 95% CI) Totals not select-
ed
1.11 Disability: moderate to severe dis-
ability at end of treatment
1 111 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.11.1 Modified Rankin Scale 1 111 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.12 Adverse events: death 9 496 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.32, 4.91]
1.12.1 At end of treatment 9 496 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.32, 4.91]
1.13 Adverse events: all 9   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.13.1 Central nervous system events (e.g.
confusion, sedation, tremor)
4 214 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.51, 3.15]
1.13.2 Gastrointestinal effects (e.g. consti-
pation, diarrhoea)
6 383 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.67, 2.19]
1.13.3 Recurrent stroke 2 114 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.25, 8.80]
1.13.4 Vascular events - not stroke (e.g.
dizziness, palpitation)
3 282 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.84, 1.50]
1.13.5 Psychiatric events (e.g. anxiety, in-
creased depression)
1 100 Risk Ratio (M-H, Random, 95% CI) 4.81 [0.24, 97.68]
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Statistical method Effect size
1.13.6 Other events - not listed above (e.g.
dysuria, eye discomfort)
3 190 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.44, 2.85]
1.13.7 Protocol violation (e.g. refused
treatment, withdrew consent)
5 309 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.62, 1.27]
1.14 Adverse events: leaving the study
early (including death)
12 836 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.84, 1.26]
1.14.1 All dropouts and withdrawals 12 836 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.84, 1.26]
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Analysis 1.1.   Comparison 1: Pharmacological interventions (antidepressants) versus
placebo, Outcome 1: Depression: meeting study criteria for depression at end treatment
Study or Subgroup





Test for overall effect: Z = 1.52 (P = 0.13)





Test for overall effect: Z = 2.80 (P = 0.005)






Heterogeneity: Tau² = 0.00; Chi² = 1.24, df = 2 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.13 (P = 0.26)





Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 2.95 (P = 0.003)





Test for overall effect: Z = 0.71 (P = 0.48)





Test for overall effect: Z = 1.86 (P = 0.06)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 6.06, df = 8 (P = 0.64); I² = 0%
Test for overall effect: Z = 4.43 (P < 0.00001)

























































































M-H, Random, 95% CI
0.62 [0.34 , 1.15]
0.62 [0.34 , 1.15]
0.45 [0.26 , 0.79]
0.45 [0.26 , 0.79]
0.96 [0.30 , 3.11]
0.47 [0.12 , 1.84]
0.27 [0.03 , 2.51]
0.62 [0.27 , 1.42]
0.39 [0.15 , 1.03]
0.25 [0.08 , 0.80]
0.33 [0.15 , 0.69]
0.74 [0.32 , 1.70]
0.74 [0.32 , 1.70]
0.14 [0.02 , 1.12]
0.14 [0.02 , 1.12]
0.50 [0.37 , 0.68]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
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Analysis 1.2.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo,







M-H, Random, 95% CI
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.3.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo,
Outcome 3: Depression: average change in scores between baseline and end of treatment
Study or Subgroup






Heterogeneity: Tau² = 0.00; Chi² = 1.30, df = 3 (P = 0.73); I² = 0%
Test for overall effect: Z = 0.76 (P = 0.45)




Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.78, df = 4 (P = 0.78); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)























































IV, Random, 95% CI
-0.38 [-1.22 , 0.46]
-0.26 [-1.07 , 0.56]
0.25 [-0.59 , 1.10]
-0.26 [-1.12 , 0.60]
-0.16 [-0.58 , 0.26]
0.04 [-0.34 , 0.41]
0.04 [-0.34 , 0.41]
-0.05 [-0.33 , 0.23]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.4.   Comparison 1: Pharmacological interventions (antidepressants)
versus placebo, Outcome 4: Depression: mean scores at end of treatment
Study or Subgroup






Heterogeneity: Tau² = 0.00; Chi² = 2.07, df = 3 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.07, df = 3 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.56 (P = 0.57)













































IV, Random, 95% CI
-0.60 [-5.26 , 4.06]
3.50 [-1.05 , 8.05]
-0.30 [-3.96 , 3.36]
0.30 [-3.48 , 4.08]
0.59 [-1.46 , 2.63]
0.59 [-1.46 , 2.63]
Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours pharmacotherapy Favours placebo
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Analysis 1.5.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo,
Outcome 5: Cognition: average change in scores between baseline and end of treatment
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 2 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 2 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.19 (P = 0.85)






































IV, Random, 95% CI
0.00 [-1.29 , 1.29]
0.40 [-2.87 , 3.67]
0.50 [-2.79 , 3.79]
0.11 [-1.02 , 1.24]
0.11 [-1.02 , 1.24]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.6.   Comparison 1: Pharmacological interventions (antidepressants)
versus placebo, Outcome 6: Cognition: Mean scores at end of treatment
Study or Subgroup




Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)































IV, Random, 95% CI
-0.70 [-4.63 , 3.23]
-0.30 [-2.92 , 2.32]
-0.42 [-2.60 , 1.76]
-0.42 [-2.60 , 1.76]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours placebo Favours pharmacotherapy
 
 
Analysis 1.7.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo,
Outcome 7: Activities of daily living: average change in scores between baseline and end of treatment
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 1.63, df = 2 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.63, df = 2 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.80)






































IV, Random, 95% CI
-4.50 [-17.26 , 8.26]
7.60 [-5.92 , 21.12]
1.00 [-33.23 , 35.23]
1.18 [-7.77 , 10.14]
1.18 [-7.77 , 10.14]
Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours pharmacotherapy Favours placebo
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Analysis 1.8.   Comparison 1: Pharmacological interventions (antidepressants)
versus placebo, Outcome 8: Activities of daily living: mean scores at end of treatment
Study or Subgroup




Heterogeneity: Tau² = 33.68; Chi² = 1.52, df = 1 (P = 0.22); I² = 34%
Test for overall effect: Z = 0.11 (P = 0.91)




Test for overall effect: Z = 4.62 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 9.36; Chi² = 2.57, df = 2 (P = 0.28); I² = 22%
Test for overall effect: Z = 1.34 (P = 0.18)









































IV, Random, 95% CI
7.80 [-8.01 , 23.61]
-6.20 [-21.83 , 9.43]
0.75 [-12.97 , 14.47]
-5.18 [-7.38 , -2.98]
-5.18 [-7.38 , -2.98]
-3.86 [-9.48 , 1.77]
Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.9.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo,
Outcome 9: Disability: average change in scores between baseline and end of treatment
Study or Subgroup
1.9.1 Hemispheric Stroke Scale Total Score (high score = more neurological deficit)
Dam 1996a
Dam 1996b
1.9.2 Hemispheric Stroke Scale Motor Subscale (high score = more deficit)
Dam 1996a
Dam 1996b
1.9.3 Hemispheric Stroke Scale Gait Subscale (high score = more deficit)
Dam 1996a
Dam 1996b




























































IV, Random, 95% CI
-0.30 [-8.47 , 7.87]
-1.10 [-10.13 , 7.93]
0.90 [-2.93 , 4.73]
0.70 [-3.22 , 4.62]
-0.90 [-1.57 , -0.23]
0.30 [-0.54 , 1.14]
-1.30 [-4.57 , 1.97]
-0.50 [-3.65 , 2.65]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours pharmacotherapy Favours placebo
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Analysis 1.10.   Comparison 1: Pharmacological interventions (antidepressants)
versus placebo, Outcome 10: Disability: mean scores at end of treatment
Study or Subgroup
1.10.1 Hemispheric Stroke Scale total score (high score = more neurological deficit)
Dam 1996a
Dam 1996b
1.10.2 Hemispheric Stroke Scale motor subscale (high score = more deficit)
Dam 1996a
Dam 1996b
1.10.3 Hemispheric Stroke Scale gait subscale (high score = more deficit)
Dam 1996a
Dam 1996b




























































IV, Random, 95% CI
-2.70 [-10.82 , 5.42]
1.50 [-7.71 , 10.71]
0.80 [-3.08 , 4.68]
0.60 [-3.36 , 4.56]
-0.80 [-1.79 , 0.19]
0.20 [-0.91 , 1.31]
0.90 [-1.96 , 3.76]
-0.50 [-3.13 , 2.13]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.11.   Comparison 1: Pharmacological interventions (antidepressants) versus
placebo, Outcome 11: Disability: moderate to severe disability at end of treatment
Study or Subgroup









Test for overall effect: Not applicable


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
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Analysis 1.12.   Comparison 1: Pharmacological interventions
(antidepressants) versus placebo, Outcome 12: Adverse events: death
Study or Subgroup












Heterogeneity: Tau² = 0.00; Chi² = 2.46, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.75)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 2.46, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.75)



























































M-H, Random, 95% CI
2.00 [0.19 , 20.67]
Not estimable
Not estimable
0.96 [0.06 , 14.94]
Not estimable
Not estimable
5.08 [0.25 , 103.68]
Not estimable
0.20 [0.01 , 4.01]
1.25 [0.32 , 4.91]
1.25 [0.32 , 4.91]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
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Analysis 1.13.   Comparison 1: Pharmacological interventions (antidepressants) versus placebo, Outcome 13:
Adverse events: all
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 1.90, df = 3 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.62)









Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 5 (P = 0.96); I² = 0%






Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)






Heterogeneity: Tau² = 0.00; Chi² = 0.79, df = 2 (P = 0.68); I² = 0%
Test for overall effect: Z = 0.80 (P = 0.42)





Test for overall effect: Z = 1.02 (P = 0.31)






Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 2 (P = 0.71); I² = 0%






































































































































M-H, Random, 95% CI
3.32 [0.19 , 57.61]
1.35 [0.46 , 3.96]
1.69 [0.08 , 37.26]
0.21 [0.01 , 4.13]
1.26 [0.51 , 3.15]
3.00 [0.13 , 70.30]
1.42 [0.06 , 31.57]
1.92 [0.18 , 20.52]
1.50 [0.07 , 33.26]
1.06 [0.55 , 2.05]
3.09 [0.13 , 73.19]
1.21 [0.67 , 2.19]
2.00 [0.19 , 20.67]
1.00 [0.07 , 15.30]
1.49 [0.25 , 8.80]
2.88 [0.12 , 69.16]
1.11 [0.83 , 1.48]
3.09 [0.13 , 73.19]
1.13 [0.84 , 1.50]
4.81 [0.24 , 97.68]
4.81 [0.24 , 97.68]
1.35 [0.46 , 3.96]
0.94 [0.10 , 8.92]
0.34 [0.01 , 8.13]
1.12 [0.44 , 2.85]
Risk Ratio
M-H, Random, 95% CI
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Analysis 1.13.   (Continued)
Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.25 (P = 0.80)








Heterogeneity: Tau² = 0.00; Chi² = 1.23, df = 4 (P = 0.87); I² = 0%































0.91 [0.63 , 1.33]
0.67 [0.12 , 3.65]
0.32 [0.03 , 2.98]
1.50 [0.07 , 33.26]
1.69 [0.08 , 37.26]
0.89 [0.62 , 1.27]
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
 
 
Analysis 1.14.   Comparison 1: Pharmacological interventions (antidepressants)
versus placebo, Outcome 14: Adverse events: leaving the study early (including death)
Study or Subgroup















Heterogeneity: Tau² = 0.00; Chi² = 4.13, df = 11 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 4.13, df = 11 (P = 0.97); I² = 0%
Test for overall effect: Z = 0.30 (P = 0.76)















































































M-H, Random, 95% CI
0.91 [0.63 , 1.33]
1.00 [0.28 , 3.56]
2.37 [0.13 , 44.40]
1.59 [0.19 , 13.15]
0.86 [0.38 , 1.95]
0.96 [0.69 , 1.33]
1.88 [0.25 , 14.24]
2.81 [0.15 , 52.38]
1.42 [0.48 , 4.23]
0.69 [0.12 , 3.85]
1.40 [0.83 , 2.36]
1.33 [0.32 , 5.49]
1.03 [0.84 , 1.26]
1.03 [0.84 , 1.26]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours pharmacotherapy Favours placebo
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Comparison 2.   Psychological therapy versus standard care and/or attention control





Statistical method Effect size
2.1 Depression: meeting study criteria
for depression at end of treatment
2 607 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.49, 0.94]
2.1.1 PSE (high score = probable psy-
chiatric disorder)
1 450 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.46, 1.12]
2.1.2 GHQ-28 (high score = greater
psychological distress)
1 157 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.39, 1.03]
2.2 Scoring above cut-oE points for
a depressive disorder at end of treat-
ment
0   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.3 Depression: mean scores at end of
treatment
2   Mean Difference (IV, Random, 95% CI) Totals not selected
2.3.1 HADS (high score = more de-
pressed)
2   Mean Difference (IV, Random, 95% CI) Totals not selected
2.3.2 MADRS (high score = more de-
pressed)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2.4 Depression: mean scores at end of
follow-up
3   Mean Difference (IV, Random, 95% CI) Totals not selected
2.4.1 HADS (high score = more de-
pressed)
3   Mean Difference (IV, Random, 95% CI) Totals not selected
2.4.2 PHQ-9 (high score = more de-
pressed)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2.4.3 MADRS (high score = more de-
pressed)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
2.5 Psychological distress: average
change in scores between baseline
and end of treatment
2 607 Mean Difference (IV, Random, 95% CI) -1.37 [-2.27, -0.48]
2.5.1 GHQ-28 (high score = greater
psychological distress)
2 607 Mean Difference (IV, Random, 95% CI) -1.37 [-2.27, -0.48]
2.6 Psychological distress: mean
scores at end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.6.1 GHQ-28 (high score = greater
psychological distress)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.7 General Health: average change in
scores between baseline and end of
treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.7.1 Nottingham Health Profile (high
score = better health)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Statistical method Effect size
2.8 General Health: Mean scores at
end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.8.1 Nottingham Health Profile (high
score = better health)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.9 Social activities: average change
in scores between baseline and end
of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.9.1 Frenchay Activities Index (high
score = better level of activity)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.10 Social activities: mean scores at
end of treatment
2 690 Mean Difference (IV, Random, 95% CI) -0.39 [-3.81, 3.03]
2.10.1 Frenchay Activities Index (high
score = better level of activity)
2 690 Mean Difference (IV, Random, 95% CI) -0.39 [-3.81, 3.03]
2.11 Activities of daily living: Average
change in scores between baseline
and end of treatment
3 847 Mean Difference (IV, Random, 95% CI) 0.29 [-0.18, 0.77]
2.11.1 Barthel Index (high score =
more dependent)
3 847 Mean Difference (IV, Random, 95% CI) 0.29 [-0.18, 0.77]
2.12 Activities of daily living: mean
scores at end of treatment
4   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.12.1 Barthel Index (high score =
more dependent)
3   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.12.2 Modified Barthel Index (high
score = more dependent)
1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.12.3 Nottingham Extended Activi-
ties of daily living (high score = more
independent)
1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.13 Activities of daily living: mean
scores at end of follow-up
1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.13.1 Modified Barthel Index (high
score = more dependent)
1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.13.2 Nottingham Extended Activi-
ties of daily living (high score = more
independent)
1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.14 Anxiety: mean scores at end of
treatment
2   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.14.1 HADS (high score = more anx-
ious)
2   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
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Statistical method Effect size
2.14.2 STI Trait Anxiety 1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.14.3 STI State Anxiety 1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.15 Anxiety: mean scores at end of
follow-up
3   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.15.1 HADS (high score = more anx-
ious)
3   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.15.2 STI Trait Anxiety 1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.15.3 STI State Anxiety 1   Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.16 Adverse events: death 5 975 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.73, 1.91]
2.16.1 At end of treatment 5 975 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.73, 1.91]
2.17 Adverse events: all 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.17.1 Recurrent stroke 2 212 Risk Ratio (M-H, Random, 95% CI) 2.61 [0.88, 7.70]
2.17.2 Vascular events - not stroke
(e.g. transient ischaemic attack)
1 157 Risk Ratio (M-H, Random, 95% CI) 6.23 [0.77, 50.59]
2.18 Adverse events: leaving the
study early (including death)
6 1030 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.90, 1.88]
2.18.1 All dropouts and withdrawals 6 1030 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.90, 1.88]
 
 
Analysis 2.1.   Comparison 2: Psychological therapy versus standard care and/or attention
control, Outcome 1: Depression: meeting study criteria for depression at end of treatment
Study or Subgroup





Test for overall effect: Z = 1.48 (P = 0.14)





Test for overall effect: Z = 1.85 (P = 0.06)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df = 1 (P = 0.73); I² = 0%
Test for overall effect: Z = 2.34 (P = 0.02)


































M-H, Random, 95% CI
0.71 [0.46 , 1.12]
0.71 [0.46 , 1.12]
0.64 [0.39 , 1.03]
0.64 [0.39 , 1.03]
0.68 [0.49 , 0.94]
Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favours psychological the Favours usual care/attent
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Analysis 2.2.   Comparison 2: Psychological therapy versus standard care and/or attention







M-H, Random, 95% CI
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours psychological the Favours usual care/attent
 
 
Analysis 2.3.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 3: Depression: mean scores at end of treatment
Study or Subgroup
2.3.1 HADS (high score = more depressed)
Hoffman 2015
Wichowicz 2017





























IV, Random, 95% CI
1.65 [1.06 , 2.24]
-1.63 [-3.02 , -0.24]
-0.43 [-1.34 , 0.48]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.4.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 4: Depression: mean scores at end of follow-up
Study or Subgroup




2.4.2 PHQ-9 (high score = more depressed)
Kerr 2018









































IV, Random, 95% CI
-6.37 [-7.24 , -5.50]
0.80 [-3.34 , 4.94]
0.00 [-1.90 , 1.90]
1.00 [-3.80 , 5.80]
-0.98 [-1.91 , -0.05]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
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Analysis 2.5.   Comparison 2: Psychological therapy versus standard care and/or attention control,
Outcome 5: Psychological distress: average change in scores between baseline and end of treatment
Study or Subgroup




Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 3.01 (P = 0.003)































IV, Random, 95% CI
-1.41 [-2.50 , -0.32]
-1.30 [-2.87 , 0.27]
-1.37 [-2.27 , -0.48]
-1.37 [-2.27 , -0.48]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.6.   Comparison 2: Psychological therapy versus standard care and/or
attention control, Outcome 6: Psychological distress: mean scores at end of treatment
Study or Subgroup

















IV, Fixed, 95% CI
-1.14 [-2.17 , -0.11]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.7.   Comparison 2: Psychological therapy versus standard care and/or attention control,
Outcome 7: General Health: average change in scores between baseline and end of treatment
Study or Subgroup

















IV, Fixed, 95% CI
-1.80 [-27.54 , 23.94]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.8.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 8: General Health: Mean scores at end of treatment
Study or Subgroup

















IV, Fixed, 95% CI
4.60 [-21.25 , 30.45]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours psychological the Favours usual care/attent
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Analysis 2.9.   Comparison 2: Psychological therapy versus standard care and/or attention control,
Outcome 9: Social activities: average change in scores between baseline and end of treatment
Study or Subgroup

















IV, Fixed, 95% CI
-0.89 [-2.90 , 1.12]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.10.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 10: Social activities: mean scores at end of treatment
Study or Subgroup




Heterogeneity: Tau² = 4.85; Chi² = 4.90, df = 1 (P = 0.03); I² = 80%
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI)
Heterogeneity: Tau² = 4.85; Chi² = 4.90, df = 1 (P = 0.03); I² = 80%
Test for overall effect: Z = 0.22 (P = 0.82)































IV, Random, 95% CI
1.36 [-0.84 , 3.56]
-2.13 [-4.30 , 0.04]
-0.39 [-3.81 , 3.03]
-0.39 [-3.81 , 3.03]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
 
 
Analysis 2.11.   Comparison 2: Psychological therapy versus standard care and/or attention control,
Outcome 11: Activities of daily living: Average change in scores between baseline and end of treatment
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 1.21 (P = 0.22)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 1.21 (P = 0.22)






































IV, Random, 95% CI
-0.10 [-1.24 , 1.04]
0.37 [-0.20 , 0.94]
0.40 [-0.90 , 1.70]
0.29 [-0.18 , 0.77]
0.29 [-0.18 , 0.77]
Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours psychological the Favours usual care/attent
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Analysis 2.12.   Comparison 2: Psychological therapy versus standard care and/or
attention control, Outcome 12: Activities of daily living: mean scores at end of treatment
Study or Subgroup




2.12.2 Modified Barthel Index (high score = more dependent)
Hoffman 2015









































IV, Random, 95% CI
0.11 [-0.14 , 0.36]
-0.16 [-0.35 , 0.04]
0.22 [-0.10 , 0.53]
1.73 [0.47 , 2.99]
-0.70 [-1.79 , 0.40]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours psychological the Favours usual care/attent
 
 
Analysis 2.13.   Comparison 2: Psychological therapy versus standard care and/or
attention control, Outcome 13: Activities of daily living: mean scores at end of follow-up
Study or Subgroup
2.13.1 Modified Barthel Index (high score = more dependent)
Hoffman 2015























IV, Fixed, 95% CI
-0.14 [-1.23 , 0.96]
-0.51 [-1.62 , 0.61]
Std. Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours psychological the Favours usual care/attent
 
 
Analysis 2.14.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 14: Anxiety: mean scores at end of treatment
Study or Subgroup
2.14.1 HADS (high score = more anxious)
Hoffman 2015
Wichowicz 2017
2.14.2 STI Trait Anxiety
Hoffman 2015



































IV, Random, 95% CI
0.49 [-0.58 , 1.57]
-0.29 [-0.69 , 0.10]
0.04 [-1.01 , 1.10]
0.59 [-0.49 , 1.68]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours psychological the Favours usual care/attent
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Analysis 2.15.   Comparison 2: Psychological therapy versus standard care and/
or attention control, Outcome 15: Anxiety: mean scores at end of follow-up
Study or Subgroup




2.15.2 STI Trait Anxiety
Hoffman 2015









































IV, Random, 95% CI
-1.28 [-2.45 , -0.10]
0.17 [-0.58 , 0.91]
0.00 [-0.39 , 0.39]
0.27 [-0.79 , 1.33]
0.84 [-0.27 , 1.95]
Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours psychological the Favours usual care/attent
 
 
Analysis 2.16.   Comparison 2: Psychological therapy versus standard
care and/or attention control, Outcome 16: Adverse events: death
Study or Subgroup








Heterogeneity: Tau² = 0.00; Chi² = 3.06, df = 4 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 3.06, df = 4 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)












































M-H, Random, 95% CI
1.80 [0.62 , 5.21]
1.09 [0.61 , 1.95]
3.00 [0.13 , 67.91]
0.26 [0.03 , 2.27]
1.92 [0.18 , 20.52]
1.18 [0.73 , 1.91]
1.18 [0.73 , 1.91]
Risk Ratio
M-H, Random, 95% CI
0.05 0.2 1 5 20
Favours psychological the Favours usual care/attent
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Analysis 2.17.   Comparison 2: Psychological therapy versus standard







Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.83); I² = 0%
Test for overall effect: Z = 1.73 (P = 0.08)







































M-H, Random, 95% CI
2.77 [0.82 , 9.34]
2.08 [0.19 , 22.45]
2.61 [0.88 , 7.70]
6.23 [0.77 , 50.59]
6.23 [0.77 , 50.59]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours psychological the Favours usual care/attent
 
 
Analysis 2.18.   Comparison 2: Psychological therapy versus standard care and/or
attention control, Outcome 18: Adverse events: leaving the study early (including death)
Study or Subgroup









Heterogeneity: Tau² = 0.05; Chi² = 6.80, df = 5 (P = 0.24); I² = 27%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.05; Chi² = 6.80, df = 5 (P = 0.24); I² = 27%
Test for overall effect: Z = 1.41 (P = 0.16)

















































M-H, Random, 95% CI
2.00 [0.70 , 5.68]
0.78 [0.31 , 1.95]
1.37 [0.93 , 2.03]
4.00 [1.03 , 15.60]
0.26 [0.03 , 2.27]
1.19 [0.72 , 1.97]
1.30 [0.90 , 1.88]
1.30 [0.90 , 1.88]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours psychological the Favours usual care/attent
 
 
Comparison 3.   Pharmacological interventions (psychostimulants) versus placebo





Statistical method Effect size
3.1 Depression: average change in
scores between baseline and end of
treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1.1 HDRS (high score = more de-
pressed)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1.2 ZDS (high score = more depressed) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Statistical method Effect size
3.2 Cognition: average change in scores
between baseline and end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.2.1 MMSE (low score = cognitive im-
pairment)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3 Disability: average change in scores
between baseline and end of treatment
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3.1 Fugl-Meyer Scale (high score = bet-
ter function)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.3.2 Functional Independence Measure
(high score = independence)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.4 Adverse events: death 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.4.1 At end of treatment 1 21 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.5 Adverse events: leaving the study
early (including death)
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.5.1 All dropouts and withdrawals 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3: Pharmacological interventions (psychostimulants) versus placebo,
Outcome 1: Depression: average change in scores between baseline and end of treatment
Study or Subgroup
3.1.1 HDRS (high score = more depressed)
Grade 1998























IV, Fixed, 95% CI
5.14 [0.97 , 9.31]
6.02 [0.27 , 11.77]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours pharmacotherapy Favours placebo
 
 
Analysis 3.2.   Comparison 3: Pharmacological interventions (psychostimulants) versus placebo,
Outcome 2: Cognition: average change in scores between baseline and end of treatment
Study or Subgroup

















IV, Fixed, 95% CI
-0.60 [-2.48 , 1.28]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours pharmacotherapy Favours placebo
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Analysis 3.3.   Comparison 3: Pharmacological interventions (psychostimulants) versus placebo,
Outcome 3: Disability: average change in scores between baseline and end of treatment
Study or Subgroup
3.3.1 Fugl-Meyer Scale (high score = better function)
Grade 1998























IV, Fixed, 95% CI
17.48 [0.52 , 34.44]
11.51 [1.85 , 21.17]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours pharmacotherapy Favours placebo
 
 
Analysis 3.4.   Comparison 3: Pharmacological interventions
(psychostimulants) versus placebo, Outcome 4: Adverse events: death
Study or Subgroup


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
 
 
Analysis 3.5.   Comparison 3: Pharmacological interventions (psychostimulants)
versus placebo, Outcome 5: Adverse events: leaving the study early (including death)
Study or Subgroup













M-H, Fixed, 95% CI
1.10 [0.08 , 15.36]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours pharmacotherapy Favours placebo
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Methods Participants Interventions Out-
comes
Notes
Table 1.   Characteristics of dropout studies 
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression a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Number of participants: 30
Stroke criteria: acute stroke
Method of stroke diagnosis: not report-
ed
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: not reported
Number included in treatment group:
unclear (63% male, mean age 72.2, SD
not reported of the overall cohort)
Number included in control group: un-
clear (63% men, mean age 72.2, SD not










































Number of participants: 62
Stroke criteria: not reported
Method of stroke diagnosis: not report-
ed
Inclusion criteria: 1) lived at home;
2) had an informal carer; 3) stroke in-
crease mRS; 4) post-stroke mRS score
of 2 to 5
Exclusion criteria: 1) not living at
home; 2) not having an informal car-
er; 3) having no increase in disability or
change in lifestyle/dependency
Depression criteria: HADS score > 11
Number included in treatment group
1: 22 (50% men, age not reported)
Number included in treatment group
2: 22 (55% men, age not reported)
Number included in control group: 18
(44% men, age not reported)
Treatment 1: information plus
counselling. Egan's problem-solv-
ing approach, individual is helped
to explore concerns, clarify prob-
lems, set goals, and take appro-
priate action. Protocol discussed
first and formulated into a coun-
sellor/client contract. Information
pack containing information on
physical, cognitive, behavioural
and emotional effects of stroke,
carer well-being, and local ser-
vices.
Treatment 2: information only: in-
formation pack containing infor-
mation on physical, cognitive,be-
havioural, and emotional effects of
stroke, carer well-being, and local
services.
Control: usual care, no visit(s) or
information pack provided
Duration: information session con-
sisted of 1 visit and provision of
the information pack. Counselling
consisted of up to 8 counselling
sessions over 4 to 6 months













































Number of participants: 88
Stroke criteria: all subtypes
Method of stroke diagnosis: via clinical
signs
Inclusion criteria: 1) completed formal
inpatient rehabilitation and a period of
Treatment: psychoeducational,
with participant and members of
their support team; work to im-
prove social support, establish
new supports, emotional support
offered
Control: usual care, no visits
Duration: treatment continued for

















Table 1.   Characteristics of dropout studies  (Continued)
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rehabilitation provided by a home care
programme
Exclusion criteria: 1) history of psychi-
atric admission, 2) previously on an-
tidepressant medication, 3) aphasia
with limited ability to communicate
verbally
Depression criteria: unclear
Number included in treatment group:
48 (44% men, mean age 69 years, SD
11)
Number included in control group: 40
(44% men, mean age 69 years, SD 11)
Administered by: specially trained
social support intervention thera-
pist
Supervision: unclear























Number of participants: unclear
Stroke criteria: unclear




Number included in treatment group:
unclear





































Number of participants: 22
Stroke criteria: first time diagnosis of
ischaemic stroke < 48 hours
Method of stroke diagnosis: not report-
ed
Inclusion criteria: 1) Mini-Cog score of
3; ≥ 50 years of age; 2) able to read and
write in English
Exclusion criteria: 1) previous history
of mental health problems; 2) diagno-
sis of severe aphasia as identified by a
speech pathologist; 3) haemorrhagic
stroke or transient ischaemic
attack; 4) medical instability requiring
transfer to critical care
Depression criteria: CES-D score mea-
sured at baseline but patients recruit-
ed regardless of their CES-D score. If
CES-D score > 10,
or suicidal ideation the primary physi-
cian was notified
Treatment: one-on-one problem
solving therapy sessions lasting
1-2 hours. Therapy entails provid-
ing patient information on impact
and guidance to enable the patient
to: identify and define the prob-
lem; brainstorm all potential so-
lutions; select the most appropri-
ate and feasible solution; create
and implement a SMART (Specific,
Measureable,
Achievable, Realistic and Time-
ly) goal; evaluate and re-view
progress in follow-up sessions
Administered by: a doctoral nurs-
ing student who received PST
training through a 13- module on-
line program adapted from a stan-
dard 3-day in person training
Supervision: principal investigator
who had undergone in person PST
training





























Table 1.   Characteristics of dropout studies  (Continued)
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression aer stroke (Review)









Cochrane Database of Systematic Reviews
Number included in treatment group:
11 (18% men, mean age 73)
Number included in control group: 11
(45% men, mean age 69)
Control: weekly telephone calls to
assess CES-D and FIM scores
Duration: once per week for 10
weeks
Follow-up: 3 months













Geographical location: South Korea
Setting: inpatient
Number of participants: 478
Stroke criteria: ischaemic stroke or in-
tracerebral haemorrhage
Method of stroke diagnosis: confirmed
by MRI or CT
Inclusion criteria: 1) > 20 years, 2) had
an acute ischaemic stroke or intracere-
bral haemorrhage within the previous
21 days, 3) mRS score of 2 or greater at
the time of screening, 4) agreed to par-
ticipate
Exclusion criteria: 1) history of diag-
nosed depression or other psychiatric
diseases before the index stroke, 2) se-
vere dementia, 3) cognitive dysfunc-
tion (stages 5-7 of the Global Deterio-
ration Scale), 4) aphasia, 5) on antimi-
graine or antiepileptic medication, 6)
suicidal thoughts (a combined MADRS
score > 8, 7) pregnant or lactating, 8)
participation in another clinical trial
Depression criteria: MADRS
Number included in treatment group:
241





































































Number of participants: unclear
Stroke criteria: unclear
Treatment 1: social support (infor-
mation, practical advice, service li-
aison)
Treatment 2: psychological sup-
















Table 1.   Characteristics of dropout studies  (Continued)
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Method of stroke diagnosis: unclear
Inclusion criteria: unclear
Exclusion criteria: unclear
Number included in treatment group
1: unclear
Number included in treatment group
2: unclear
Number included in treatment group
3: unclear
Number included in control group: un-
clear
Treatment 3: social support and
psychological support


































Number of participants: 40
Stroke criteria: unclear
Method of stroke diagnosis: unclear
Inclusion criteria: unclear
Exclusion criteria: unclear
Number included in treatment group:
20
Number included in control group: 20
Treatment: psychosocial, address-
es cognitive, behavioural and fam-
ily factors associated with post
stroke depression
Control: usual care, no visits































Number of participants: 188
Stroke criteria: all subtypes
Method of stroke diagnosis: diagnosis
via clinical signs and CT
Inclusion criteria: 1) > 40 years of age,
high blood pressure (> 160/90 mmHg)
and hypertensive changes on fun-
doscopy changes; 2) stable neurolep-
tic, minor tranquilliser, antidepressant,
brain metabolic activators, cerebro-va-
sodilators washed out for 3 to 7 days
prior to randomisation
Treatment: tiapride, 75 mg daily
for 1 week, dose escalation to 150
mg to 225 mg daily for 5 weeks ac-
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Exclusion criteria: 1) severe aphasia; 2)
severe dementia; 3) drug dependence;
4) inadequate conditions for the study
Depression criteria: not reported
Number included in treatment group:
141 (54% men, mean age not reported)
Number included in control group: 147






















Number of participants: 159
Stroke criteria: stroke <12 months ago,
subtype unclear
Method of stroke diagnosis: unclear
Inclusion criteria: 1) > 50 years of age
Exclusion criteria: 1) global aphasia,
2) patient or carer had comorbidity
that took priority, 3) < 6 months life ex-
pectancy
Depression criteria: none
Number included in treatment group:
79 (69% men, mean age 67 years)
Number included in control group: 80
(81% men, mean age 66 years)
Treatment: home-based psychoe-
ducational programme for stroke-
care-giving dyads post-discharge.
The intervention involved home
visits by advance practice nurses,
occupational and physical thera-
pists
Administered by: advance practice
nurses, occupational and physical
therapists
Supervision: not reported


























































Number of participants: 22
Stroke criteria: unclear
Method of stroke diagnosis: not report-
ed
Inclusion criteria: not reported
Exclusion criteria: not reported
Depression criteria: ZDS
Number included in treatment group:
11 (45.4% men, mean age 69.5, SD 2.3)
Number included in control group: 11
(72.7% men, mean age 70.4, SD 3.0)






























Table 1.   Characteristics of dropout studies  (Continued)
BI: Barthel Index
CES-D: Center for Epidemiological Studies- Depression
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CT: computed tomography
FIM: Functional Independence Measure
GDS: 15-item Geriatric Depression Scale
GHQ-12: 12 item General Health Questionnaire
GHQ-28: 28 item General Health Questionnaire
HADS: Hospital Anxiety and Depression Scale
HDRS: Hamilton Depression Rating Scale
MADRS: Montgomery-Asberg Depression Rating Scale
MRI: magnetic resonance imaging
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
SD: Standard Deviation
SF-36: 36-item Short Form Questionnaire
SSRI: selective serotonin reuptake inhibitors
ZDS: Zund Depression Scale
 
 
A P P E N D I C E S
Appendix 1. Search Review: 2008
Electronic searches
Cochrane Stroke trial register searched October 2007; Cochrane Anxiety and Neurosis trial register searched February 2008.
We searched the remaining databases in May 2006:





• Applied Science and Technology Plus
• Arts and Humanities Index
• Biological Abstracts
• BIOSIS Previews
• General Science Plus
• Science Citation Index
• Social Sciences Citation Index
• ISI Web of Science
• Dissertations and Theses
The following search strategy with a combination of controlled vocabulary and free text terms for MEDLINE and CINAHL (Ovid), and
modified it to suit the other databases.
1. exp cerebrovascular disorders/
2. (stroke$ or poststroke$ or cva$).tw.
3. (cerebrovascular$ or cerebral vascular).tw.
4. (cerebral or cerebellar or brain$ or vertebrobasilar).tw.
5. (infarct$ or isch?emi$ or thrombo$ or emboli$ or apoplexy).tw.
6. (cerebral or intracerebral or intracranial or brain$).tw.
7. (haemorrhage or hemorrhage or bleed$).tw.
8. 4 and 5
9. 6 and 7
10.1 or 2 or 3 or 8 or 9
11.Depression/
12.Depression, involutional/ or Depressive disorder/ or Dysthymic disorder/
13.(depress$ or dysthymi$).tw.
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31.clinical trial phase ii.pt.
32.clinical trial phase iii.pt.













46.(versus or sham or intervention group or comparative stud$).tw.
47.or/16-46
48.15 and 47
49.limit 48 to human
Additional searches
We searched the following conference abstracts and proceedings:
• European Stroke Conferences (2000 to 2007)
• Stroke Society of Australasia Annual Scientific Meetings (1999 to 2007)






We searched reference lists of relevant studies to identify studies not already included.
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Personal communication
We contacted professional bodies, authors of included studies, and pharmaceutical companies for information on published and
unpublished information.
Appendix 2. Search Review 2018: CENTRAL
Search strategy for CENTRAL, August 2018
 
# Query
#1 [mh ˆ“cerebrovascular disorders”] or [mh “basal ganglia cerebrovascular disease”] or [mh “brain
ischemia”] or [mh “carotid
artery diseases”] or [mh “intracranial arterial diseases”] or [mh “intracranial embolism and throm-
bosis”] or [mh “intracranial
hemorrhages”] or [mh ˆstroke] or [mh “brain infarction”] or [mh ˆ“stroke, lacunar”] or [mh ˆ“va-
sospasm, intracranial”] or
[mh ˆ“vertebral artery dissection”]
#2 stroke or poststroke or “post-stroke” or cerebrovasc* or brain next vasc* or cerebral next vasc* or
cva* or apoplex* or SAH:ti,
ab,kw (Word variations have been searched)
#3 (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch*emi* or infarct* or throm-
bo* or emboli* or occlus*)
:ti,ab,kw (Word variations have been searched)
#4 (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemor-
rhage* or hemorrhage* or
haematoma* or hematoma* or bleed*):ti,ab,kw (Word variations have been searched)
#5 [mh hemiplegia] or [mh paresis]
#6 hemipleg* or hemipar* or paresis or paretic:ti,ab,kw (Word variations have been searched)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 [mh ˆ“depressive disorder”] or [mh ˆ“depressive disorder, major”] or [mh ˆ“depressive disorder,
treatment-resistant”] or [mh
ˆ“dysthymic disorder”] or [mh ˆdepression] or [mh “antidepressive agents”]
#9 depress* or dysthymi*or dysphor*or antidepress*or anti-depress*:ti,ab,kw (Word variations have
been searched)
#10 #8 or #9
#11 #7 and #10
 
 
Appendix 3. Search Review 2018: MEDLINE
Search strategy for MEDLINE, August 2018
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or stroke, lacunar/ or vasospasm, intracranial/ or vertebral artery dissection/
2. stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
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4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. depressive disorder/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or Depression/
or exp Antidepressive Agents/
9. (depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
10.8 or 9
11.Randomized Controlled Trials as Topic/
12.random allocation/
13.Controlled Clinical Trials as Topic/
14.control groups/
15.clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical











26.(clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
27.(random$ or RCT or RCTs).tw.
28.(controlled adj5 (trial$ or stud$)).tw.
29.(clinical$ adj5 trial$).tw.
30.((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31.(quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
32.((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
33.((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.





39.7 and 10 and 38
40.exp animals/ not humans.sh.
41.39 not 40
42.limit 41 to yr=“2014 -Current”
Appendix 4. Search Review 2018: Embase
Search strategy for Embase, August 2018
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/
or exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or exp cerebrovascular accident/ or exp intracranial
aneurysm/ or exp occlusive cerebrovascular disease/
2. stroke patient/ or stroke unit/
3. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
5. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
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6. hemiparesis/ or hemiplegia/
7. (hemipleg$ or hemipar$ or paresis or paretic).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. depression/ or agitated depression/ or atypical depression/ or dysphoria/ or dysthymia/ or endogenous depression/ or involutional
10.depression/ or late life depression/ or major depression/ or masked depression/ or reactive depression/ or recurrent brief depression/
or treatment resistant depression/ exp antidepressant agent/
11.(depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
12.9 or 10 or 11
13.Randomized Controlled Trial/ or “randomized controlled trial (topic)”/
14.Randomization/
15.Controlled clinical trial/ or “controlled clinical trial (topic)”/
16.control group/ or controlled study/
17.clinical trial/ or “clinical trial (topic)”/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
18.Crossover Procedure/
19.Double Blind Procedure/
20.Single Blind Procedure/ or triple blind procedure/
21.placebo/ or placebo eEect/
22.(random$ or RCT or RCTs).tw.
23.(controlled adj5 (trial$ or stud$)).tw.
24.(clinical$ adj5 trial$).tw.
25.((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
26.(quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
27.((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
28.((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.





34.8 and 12 and 33
35.(exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
36.(human/ or normal human/ or human cell/)
37.34 not 35
Appendix 5. Search Review 2018: PsycINFO
Search strategy for PsycINFO, August 2018
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma
$ or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. major depression/ or dysthymic disorder/ or endogenous depression/ or reactive depression/ or recurrent depression/ or treatment
resistant depression/ or atypical depression/ or “depression (emotion)”/
9. exp antidepressant drugs/
10.(depress$ or dysthymi$ or dysphor$ or antidepress$ or anti-depress$).tw.
11.8 or 9 or 10
12.clinical trials/ or treatment eEectiveness evaluation/ or placebo/
13.treatment outcome clinical trial.md.
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14.(random$ or RCT or RCTs).tw.
15.(controlled adj5 (trial$ or stud$)).tw.
16.(clinical$ adj5 trial$).tw.
17.((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
18.(quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
19.((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
20.((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.





26.7 and 11 and 25
Appendix 6. Search Review 2018: CINAHL
Search strategy for CINAHL, August 2018
 
# Query
S1 (MH“CerebrovascularDisorders”)OR (MH“Basal Ganglia CerebrovascularDisease+”) OR (MH“Carotid
ArteryDiseases+”)
OR (MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Dis-
eases+”) OR (MH
“Intracranial Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”)
OR (MH “Vertebral
Artery Dissections”)
S2 (MH “Stroke Patients”) OR (MH “Stroke Units”)
S3 TI (stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or
apoplex or SAH) or AB (stroke
or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or
SAH)
S4 TI (brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell*
or intracran* or
intracerebral)
S5 TI (ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus*) or AB (ischemi* or ischae-
mi* or infarct* or thrombo*
or emboli* or occlus*)
S6 S4 and S5
S7 TI (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) or AB (brain* or
cerebr* or cerebell* or
intracerebral or intracranial or subarachnoid)
S8 TI (haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed*) or AB (haemorrhage*
or hemorrhage* or
haematoma* or hematoma* or bleed*)
S9 S7 and S8
S10 (MH “Hemiplegia”)
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S11 TI (hemipleg* or hemipar* or paresis or paretic) or AB (hemipleg* or hemipar* or paresis or paretic)
S12 S1 or S2 or S3 or S6 or S9 or S10 or S11
S13 (MH “Depression”) OR (MH “Depression, Reactive”) OR (MH “Dysthymic Disorder”)
S14 (MH “Antidepressive Agents+”)
S15 TI (depress* or dysthymi*or dysphor*or antidepress*or anti-depress* ) OR AB ( depress* or dysthy-
mi*or dysphor*or antidepress*
or anti-depress*)
S16 S13 OR S14 OR S15
S17 (MH "Randomized Controlled Trials") or (MH “Random Assignment”) or (MH “Random Sample+”)
S18 (MH "Clinical Trials") or (MH “Intervention Trials”) or (MH “Therapeutic Trials”)
S19 (MH "Double-blind Studies") or (MH “Single-Blind Studies”) or (MH “Triple-Blind Studies”)
S20 (MH "Control (Research)") or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”)
S21 (MH “Crossover Design”) OR (MH “Quasi-Experimental Studies”)
S22 PT (clinical trial or randomized controlled trial)
S23 TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
S24 TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
S25 TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
S26 TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB
((control or treatment
or experiment* or intervention) N5 (group* or subject* or patient*))
S27 TI ((control or experiment* or conservative) N5 (treatment or therapy or procedure ormanage*)) or
AB((control or experiment*
or conservative) N5 (treatment or therapy or procedure or manage*))
S28 TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or tre-
bl*) N5 (blind* or
mask*))
S29 TI (cross-over or cross over or crossover) or AB (cross-over or cross over or crossover)
S30 TI (placebo* or sham) or AB (placebo* or sham)
S31 TI trial
S32 TI (assign* or allocat*) or AB (assign* or allocat*)
S33 TI controls or AB controls
S34 TI (quasi-random* or quasi random* or pseudo-random* or pseudo random*) or AB (quasi-ran-
dom* or quasi random* or
pseudo-random* or pseudo random*)
  (Continued)
Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression aer stroke (Review)









Cochrane Database of Systematic Reviews
S35 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR
S30 OR
S31 OR S32 OR S33 OR S34 S36.S12 AND S16 AND S35
S36 S6 AND S16 AND S35
  (Continued)
 
Appendix 7. Search Review 2018: Web of Science
Search strategy for Web of Science, August 2018
We searched the following indexes Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), and Arts &
Humanities Citation Index (A&HCI) within Web of Science, from January 2002 to August 2018.
 
# Query
#1 TS=(stroke or post-stroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or
apoplex* or SAH)
#2 TS=((brain* or cerebr* or cerebell* or intracran* or intracerebral) NEAR/5 (isch$emi* or infarct* or
thrombo* or emboli* or
occlus*))
#3 TS=((brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) NEAR/5 (haem-
orrhage* or hemorrhage*
or haematoma* or hematoma* or bleed*))
#4 TS=(hemipleg* or hemipar* or paresis or paretic or hemineglect or hemi-neglect)
#5 TS=((unilateral or spatial or hemi$spatial or visual) NEAR/5 neglect)
#6 #5 OR #4 OR #3 OR #2 OR #1
#7 TS=(depress* or dysthymi*or dysphor*or antidepress*or anti-depress*)
#8 TS=(random* or RCT or RCTs)
#9 TS=(controlled NEAR/5 (trial* or stud*))
#10 TS=(clinical* NEAR/5 trial*)
#11 TS=((control or treatment or experiment* or intervention) NEAR/5 (group* or subject* or patient*))
#12 TS=(quasi-random* or quasi random* or pseudo-random* or pseudo random*)
#13 TS=((control or experiment* or conservative) NEAR/5 (treatment or therapy or procedure or man-
age*))
#14 TS=((singl* or doubl* or tripl* or trebl*) NEAR/5 (blind* or mask*))
#15 TS=(cross-over or cross over or crossover)
#16 TS=(placebo* or sham)
#17 TI=trial
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#18 TS=(assign* or allocat*)
#19 TS=controls
#20 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 or #19
#21 #6 AND #7 AND #20
  (Continued)
 
Appendix 8. Search Review 2018: Other sources
Additional searches
We searched the following conference abstracts and proceedings:
• European Stroke Conference (2011 to 2018)
• Stroke Society of Australasia Annual Scientific Meetings (2011 to 2017)
• World Stroke Congress (2000 to 2016)
• Asia Pacific Stroke Conference (2011 to 2017)
We also searched online clinical trials and research registers in August 2018
• www.ClinicalTrials.gov (https://clinicaltrials.gov/)
( depression OR low mood ) AND ( Brain Infarction OR Intracranial Hemorrhages OR Carotid Artery Diseases OR Brain Ischemia
OR Cerebral Hemorrhage OR Cerebrovascular Disorders OR Stroke )
• WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/search/en/)
Condition: stroke AND depression OR low mood
Recruitment status is: ALL
Phases are: ALL
Hide synonyms
- 9-52 DEPRESSIVE DISORDERS, BEREAVEMENT, DEPRESSED, DEPRESSED - SYMPTOM, DEPRESSED MOOD, DEPRESSED MOOD (FINDING),
DEPRESSED MOOD (PHYSICAL FINDING), DEPRESSED STATE, DEPRESSIVE DIS, DEPRESSIVE DISORDER, DEPRESSIVE DISORDER
(DISORDER), DEPRESSIVE DISORDER [DISEASE/FINDING], DEPRESSIVE DISORDER NOS, DEPRESSIVE DISORDER, NOS, DEPRESSIVE
DISORDERS, DEPRESSIVE DISORDERS NOS, DEPRESSIVE ILLNESS, DEPRESSIVE NEUROSES, DEPRESSIVE NEUROSIS, DEPRESSIVE
STATE, DEPRESSIVE STATENOS,DEPRESSIVE;DISORDER,DEPRESSIVE;NEUROSIS,DEPRESSIVE; STATE,DISORDER,DEPRESSIVE,DISORDER;
DEPRESSIVE,DISORDERS,DEPRESSIVE,DYSTHYMIC DISORDER, FEELINGBLUE, FEELINGDOWN, FEELING; DOWN, LOW MOOD, MELANCHOLY,
MISERABLE, MOOD DEPRESSED, MOOD DISORDER OF DEPRESSED TYPE, MOOD DISORDER OF DEPRESSED TYPE (DISORDER),
MOROSE MOOD, NEUROSES, DEPRESSIVE, NEUROSIS, DEPRESSIVE, NEUROSIS; DEPRESSIVE, PUSH DOWN OR DEPRESS, STATE;
DEPRESSIVE, depression - DEPRESSED, DEPRESSED MOOD, DEPRESSED MOOD (FINDING), DEPRESSED MOOD (PHYSICAL
FINDING), FEELING BLUE, FEELING DOWN, FEELING;DOWN, MELANCHOLY, MOOD DEPRESSED, MOOD DEPRESSION, MOOD
DEPRESSIONS,MOROSEMOOD, low mood - ACCIDENT CEREBROVASCULAR, ACCIDENT; CEREBRAL, ACCIDENT; CEREBROVASCULAR,
APOPLEXY, APOPLEXY, CEREBROVASCULAR, APOPLEXY; CEREBRAL, BRAIN ATTACK, BRAIN VASCULAR ACCIDENT, BRAIN VASCULAR
ACCIDENTS, CEREBRAL VASCULAR ACCIDENT, CEREBRAL VASCULAR EVENTS, CEREBRAL; ACCIDENT, CEREBRAL; APOPLEXY,
CEREBROVASCULAR ACCIDENT, CEREBROVASCULAR ACCIDENT (DISORDER), CEREBROVASCULAR ACCIDENTNOS,CEREBROVASCULAR
ACCIDENT, NOS, CEREBROVASCULAR ACCIDENTS, CEREBROVASCULAR APOPLEXY, CEREBROVASCULAR; ACCIDENT, CVA, CVA (CEREBRAL
VASCULAR ACCIDENT), CVA (CEREBROVASCULARACCIDENT),CVANOS,CVAS (CEREBROVASCULAR ACCIDENT), NEURO: CEREBROVASCULAR
ACCIDENT, VASCULAR ACCIDENT, BRAIN, VASCULAR ACCIDENTS, BRAIN, stroke
W H A T ' S   N E W
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Date Event Description
13 August 2018 New citation required and conclusions
have changed
There is very low-certainty evidence that pharmacological inter-
ventions may prevent depression and improve mood after stroke
compared to placebo.
13 August 2018 New search has been performed New co-authors: SA, KC & C-FH
New interventions included: combination psychological and
pharmacological interventions versus a single intervention, and
non-invasive brain stimulation interventions and the review title
has been updated accordingly.
The following additional outcomes: health-related quality of life
(HRQoL), as measured on scales such as the 36-item short form
questionnaire (SF-36, Ware 1993), proportion reporting depen-
dence in self-care activities of daily living (ADL) on the Modified
Rankin Scale (mRS, Rankin 1957) and principal caregiver HRQoL
and stress have been removed in this update.
Six new trials, with 417 participants included in the review. A to-
tal of 19 trials (21 interventions), with 1771 participants, are in-
cluded in the review. Data were available for 12 pharmacological
trials (14 interventions) and seven psychological therapy trials.
Covidence was used to collate and screen identified titles and
abstracts.
MH extracted additional data from previously included trials.
The searches for the review were completed to 13 August 2018.
 
H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 2, 2004
 
Date Event Description
18 March 2008 Amended Converted to new review format.
30 January 2008 New citation required and conclusions
have changed
Substantive amendment.
30 January 2008 New search has been performed Two new trials have been added: one pharmacological inter-
vention making a total of 10 pharmacological trials (12 compar-
isons), and one psychological intervention making a total of four
trials. Seven trials require more information before they can be
assessed for inclusion in the review (down from 14 in the previ-
ous version). Seven trials appear to meet review inclusion crite-
ria but information is not available in a format suitable for pool-
ing. Four trials are ongoing (up from two in the previous version).
 
C O N T R I B U T I O N S   O F   A U T H O R S
SA: contributed to writing the review, completed title screening and inclusion/exclusion review, extracted data, performed the meta-
analyses and GRADE assessment.
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KC: completed title screening and inclusion/exclusion review and data extraction.
CFH: assisted with obtaining, translating and extracting data from Chinese language studies for the current updated review.
AH: conceived the idea for the review, contributed to the development, writing, and editing of the protocol, and undertook the work
necessary to complete the 2004 and 2008 versions of the review, and edited this update.
MH: contributed to the development, writing, and editing of the protocol and undertook the work necessary to complete the 2004 and
2008 version of the review, and edited each review update.






S O U R C E S   O F   S U P P O R T
Internal sources
• The George Institute for International Health, Australia
External sources
• Stroke Society of Australasia, Overseas Study Scholarship, Australia
• Academic Unit of Psychiatry, University of Leeds, UK
• Department of Clinical Neurosciences, University of Edinburgh, UK
• Clinical Trials Research Unit, University of Auckland, New Zealand
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In this update, we expanded the review to include non-invasive brain stimulation such as 1) transcranial magnetic stimulation or repetitive
transcranial magnetic stimulation (TMS or rTMS, where a magnetic 'coil' is placed near the head of the person receiving the treatment
without making physical contact); 2) transcranial direct current stimulation (tDCS, where a constant, low current is delivered directly
to the brain area of interest via small electrodes); 3) cranial electrotherapy stimulation (CES, where a small, pulsed electric current is
applied across a person's head); and 4) magnetic seizure therapy (MST), a type of convulsive therapy that involves replacing the electrical
stimulation used in electroconvulsive therapy (ECT) with a rapidly alternating strong magnetic stimulation. We also expanded it to include
combination interventions with single interventions.
We have removed the following additional outcomes from this update: health-related quality of life (HRQoL), as measured on scales such
as the 36-item short form questionnaire (SF-36); proportion reporting dependence in self-care activities of daily living (ADL) on the Modified
Rankin Scale (mRS); and principal caregiver HRQoL and stress, as few trials included these data. Trials with these endpoints are included
in other Cochrane Reviews.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
AEect;  Depression  [*prevention & control];  Depressive Disorder  [*prevention & control];  *Psychotherapy;  Randomized Controlled
Trials as Topic;  Stroke  [*psychology]
MeSH check words
Humans
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